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EA series of per-O-benzoylated 5-b-D-glucopyranosyl-2-substituted-1,3,4-oxadiazoles was prepared byacylation of the corresponding 5-(b-D-glucopyranosyl)tetrazole. As an alternative, oxidation of 2,6-anhy-
dro-aldose benzoylhydrazones by iodobenzene I,I-diacetate afforded the same oxadiazoles. 1,3-Dipolar
cycloaddition of nitrile oxides to per-O-benzoylated b-D-glucopyranosyl cyanide gave the corresponding
5-b-D-glucopyranosyl-3-substituted-1,2,4-oxadiazoles. The O-benzoyl protecting groups were removed
by base-catalyzed transesteriﬁcation. The 1,3,4-oxadiazoles were practically inefﬁcient as inhibitors of
rabbit muscle glycogen phosphorylase b while the 1,2,4-oxadiazoles displayed inhibitory activities in
the micromolar range. The best inhibitors were the 5-b-D-glucopyranosyl-3-(4-methylphenyl- and -2-
naphthyl)-1,2,4-oxadiazoles (Ki = 8.8 and 11.6 lM, respectively). A detailed analysis of the structure–
activity relationships is presented.
 2009 Published by Elsevier Ltd.R70U
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R1. Introduction
Theworldwide increasingprevalence of Type 2DiabetesMellitus
(T2DM) has become a major health problem for most of the world’s
population.1 Several oral hypoglycemic agents2–4 (sulfonylureas,
biguanides, thiazolidinediones, a-glucosidase inhibitors5) are now
being used to help diabetic patients to reduce hyperglycemia. Such
symptomatic treatments are intended to reachnormal physiological
blood glucose levels. However, they have several undesirable side
effects and may also cause hypoglycemia.6 These drugs are inade-
quate for 30–40% of patients.7 Due to the appearance and spreading
of T2DM among young adults as well as children, the coming dec-
ades must face severe economic and health service burdens.8–10
Fuelled by all these facts, several new therapeutic possibilities are
under investigation.11–13 Among them, liver glycogen phosphory-
lase (GP), an enzyme responsible for the phosphorylative degrada-80
Elsevier Ltd.
: +36 52 453 836 (L.S.); fax:
k@tigris.klte.hu (L. Somsák),
; et al. Bioorg. Med. Chem. (2tion of glycogen, has been shown to be a target for the treatment
of T2DM.14,15 Since GP appears as the rate limiting enzyme of glyco-
gen degradation, its inhibition may offer a means for regulating
blood sugar levels.
A number of inhibitors have been discovered and designed in
recent years targeting the different binding sites identiﬁed for
GP.20,25 Among these inhibitors, a large array of glucose derivatives
binds at the catalytic site of the enzyme.20,25 Among the ﬁrst efﬁ-
cient glucose analogs were the N-acyl-glucopyranosylamines, for
example, 1a,b,h,i (Chart 1), and further inhibitor design led to
the discovery of more potent N-acyl-N0-b-D-glucopyranosyl-ureas
like 2a,b,h,i. As another class of efﬁcient molecules, we developed
several inhibitors having C-glucosyl heterocyclic structural ele-
ments such as tetrazole 3, benzimidazole 4, benzothiazole 5,
1,3,4-oxadiazole21,22 6a and 1,2,4-oxadiazoles 7a,b,i and 8b,23,24
as well as hydroquinone derivatives.26 Several of these compounds
displayed an inhibition against rabbit muscle glycogen phosphory-
lase b (RMGPb) in the low micromolar range.
In the 3-b-D-glucopyranosyl-5-substituted 1,2,4-oxadiazole
series, the 2-naphthyl derivative 7i was shown to be the best009), doi:10.1016/j.bmc.2009.04.036
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Chart 1. Inhibition of rabbit muscle glycogen phosphorylasea (RMGP) b (Ki [lM]) by selected glucose-based derivativesb.Q3
aBecause of a 80% homology between the liver and muscle isoforms of GP, it is a general practice to use the more readily available RMGP for kinetic studies.
bNumbering of molecules is based on the complete set of molecules presented in Table 1.cUnpublished results.
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inhibitor.23 This ﬁnding was similar to the observations made with
the N-acyl-b-D-glucopyranosylamines18 1a,b,h,i and N-acyl-N0-b-D-
glucopyranosyl-ureas19,20 2a,b,h,i. Especially in the latter series of
compounds, the presence of a hydrophobic aromatic appendage
properly oriented (comparing 2h to 2i) proved beneﬁcial for the
strong binding to GP. This result was explained by the favorable
interactions of the inhibitor in the so-called b-channel19 in the
vicinity of GP’s catalytic site which is an empty space surrounded
by amino-acid residues of mixed character.14,20
Since the preliminary results obtained with the two other
isomeric oxadiazoles (6a and 8b) were encouraging with respect
to GP inhibition, we planned a broader study of structure–activity
relationships of C-glucosylated oxadiazoles. We present herein the
synthesis of 5-(b-D-glycopyranosyl) derivatives of 2-substituted-
1,3,4- and 3-substituted-1,2,4-oxadiazoles with a diverse set of
aromatic residues as well as a detailed comparative analysis of
structure–activity relationships of the different isomeric oxadiaz-
ole derivatives.
2. Results and discussion
The nature of the aryl substituent of the oxadiazole ring is inﬂu-
encing the binding to the enzyme’s catalytic site. We therefore pre-
pared a series of molecules incorporating either basic (p-amino),
acidic (p-hydroxy) or neutral (p-methyl, p-methoxy, p-nitro) sub-
stituents on the phenyl residues as well as larger aromatic moieties
(1- and 2-naphthyl). The syntheses of the target oxadiazoles were
achieved using per-O-benzoylated b-D-glucopyranosyl cyanide 9 as
a common starting material.Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (22.1. Synthesis of 2-aryl-5-(D-glycopyranosyl)-1,3,4-oxadiazoles
C-Glycosyl-1,3,4-oxadiazoles were prepared earlier in various
sugar conﬁgurations by acylation of 5-(D-glycosyl)tetrazoles with
an excess of acid chlorides or anhydrides,27–29 compound 6a being
the only b-D-glucopyranosyl derivative among them.21 In the pres-
ent study, we have investigated the use of acyl chlorides in pyri-
dine or toluene, and also applied a DCC-mediated acylation by
the corresponding carboxylic acid30 (Scheme 1). The yields for
the acylation of tetrazole 10, obtained from 9 as earlier,21 were
slightly higher in pyridine than in toluene, and the DCC coupling
proved less satisfactory to get oxadiazoles 11.
A widely used method for the preparation of unsymmetrically
2,5-disubstituted-1,3,4-oxadiazoles is the oxidation of acylhydra-
zones by using a variety of oxidizing agents.31–36 This method
was extended to anhydro-aldose benzoylhydrazone 12 which
was obtained from 9 by our recently published method37 and oxi-
dized by iodobenzene I,I-diacetate (PIDA) to give oxadiazole 11b in
excellent yield (Scheme 1). The two alternative methods for getting
11b are similar in the number of synthetic steps as well as techni-
cal difﬁculties. However, route e–f gave higher overall yield as
compared to route a–b or a–d (Scheme 1). To show the applicabil-
ity of this oxidative method, anhydro-aldose benzoylhydrazones
14a–c41 were also converted to the corresponding oxadiazoles
15a–c in good yields (Scheme 2). Removal of the O-acyl protecting
groups from oxadiazoles 11 was achieved by the Zemplén protocol
to give glucopyranosyl oxadiazoles 6 (Scheme 1). Raney-nickel cat-
alyzed reduction of the nitro group in 6e afforded amino com-
pound 6f.009), doi:10.1016/j.bmc.2009.04.036
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Scheme 1. Reagents and conditions: (a) NH4N3, DMF; (b) ArCOCl, pyridine, 90 C; c) ArCOCl, toluene, reﬂux; (d) ArCOOH, DCC, toluene, reﬂux; (e) ArCONHNH2, Raney-Ni,
NaH2PO2, AcOH, H2O, pyridine, 40 C; (f) PhI(OAc)2, CH2Cl2, rt; (g) NaOMe, MeOH, rt; (h) Raney-Ni, H2, MeOH, 60 C. Yields (%) are indicated in parentheses.
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2.2. Synthesis of 3-aryl-5-(b-D-glucopyranosyl)-1,2,4-
oxadiazoles24
1,3-Dipolar cycloaddition of nitrile oxides to nitriles provides an
efﬁcient and short route to diversely substituted 1,2,4-oxadiazoles.
The nitrile oxides can be easily obtained from the corresponding
hydroximoyl chloride precursors 16which will undergo a dehydro-
halogenation in the presence of a base. The addition of the basemust
occur in the presence of the dipolarophile in order to avoid the
formation of nitrile oxide dimers. Hydroximoyl chlorides are there-
fore synthesized in a two-step process from the corresponding alde-
hydes by a reactionwith hydroxylamine hydrochloride to afford the
oxime intermediates which are then treated with N-chlorosuccini-
mide to afford the desired hydroximoyl chlorides 16 (Scheme 3).
The puriﬁcation of the oxime intermediates was required in order
to obtain reproducible results and also to reach high purity of the
hydroximoyl chlorides since their puriﬁcation by standard column
chromatographywas usually not successful due to their poor stabil-
ity. Glucosyl cyanide 9was then reactedwith the hydroximoyl chlo-
rides 16 in the presence of Et3N at low concentration in reﬂuxingU
N
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Scheme 3. Reagents and conditions: (a) NH2OHHCl, EtOH, NaOH, 70 C then NCS, DMF,
are indicated in parentheses.
Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
Dtoluene to afford the desired 1,2,4-oxadiazoles 17. The addition ofthe base was achieved at a slow rate with a syringe pump. Subse-
quent transesteriﬁcation of the benzoate esters under Zemplén con-
ditions afforded the expected 1,2,4-oxadiazoles 8 in high yields. A
small proportion (4–8%) of 1,2-endo-glycals 18b–e,i were also
isolated while their formation could not be detected for other aryl
substituents.We previously observed that a substituent at the 5-po-
sitionof the1,2,4-oxadiazole ringpossessing anacid-labilea-proton
would be susceptible of deprotonation or even b-elimination if a
leaving group is present at the b-position.22 Similar observations
weremadewithother ester protectedcarbohydratederivatives such
as glycosyl cyanides29,38–40 C-glycosyl thiadiazole41 or benzothia-
zole.29 Interestingly, this elimination was not observed in the
1,3,4-oxadiazole series 11. Finally, the reduction of the p-nitro-
phenyl-substituted derivative 8e to the corresponding p-aminophe-
nyl oxadiazole 8f was achieved under standard hydrogenation
conditions (Pd–C 10%, H2, 1 atm).
The p-benzyloxy-phenyl derivative 8j was initially prepared in
order to obtain the p-hydroxy-phenyl substituted oxadiazole 8g
through hydrogenolysis of the benzyl group. But, since the directO
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from a-chloroarylaldoxime 16g, we therefore considered the
p-benzyloxy-phenyl derivative 8j as an additional candidate for
the inhibition of GP. The benzo[1,3]dioxol-5-yl substituted 1,2,4-
oxadiazole 8k was synthesized in order to evaluate its inhibition
towards the enzyme since the hydrophobic aromatic residue could
interact with the b-channel of GP and also since this aromatic res-
idue can be found as a pharmacophore in a series of natural prod-
ucts and synthetic drugs.
2.3. Enzymatic evaluation of oxadiazoles as GP inhibitors
The kinetic parameters of the synthesized molecules were then
determined according to our previously described enzymatic pro-
tocol.26 We compared the inhibition properties of C-glucosylated
1,3,4-oxadiazoles 6 and 1,2,4-oxadiazoles 8 with the activity of
regioisomeric 1,2,4-oxadiazoles 7, N-acyl-b-D-glucopyranosylam-
ines 1 and N-acyl-N0-b-D-glucopyranosyl ureas 2 (Table 1).
In the N-acyl-N0-b-D-glucopyranosyl urea series 2, an overall
equivalent inhibition in the micromolar range was observed for
the benzoyl analogs (2b–g R = (p-substituted)phenyl). The 1-naph-
thoyl derivative 2h was a somewhat worse inhibitor of GP. AU
N
C
O
R
R
E
C
T
Table 1
Inhibition (Ki or *IC50 (lM)) of rabbit muscle glycogen phosphorylase b by N-acyl-b-D-g
glucopyranosyl)-5-substituted-1,3,4-oxadiazoles 6a–i, 3-(b-D-glucopyranosyl)-5-substitute
oles 8b–k
R
O
HO
H
N
O
R O
HO
H
N
O
H
N R
O
O
HO O
NN
CH3 1a 3216 2a 30519 6a 21221
14522
1b 8116 2b 4.619 6b 10% at 625 lM
14417
Me
1c 4500*18 2c 2.320 6c No inhibition at
OMe
— — 6d No inhibition at
NO2
— 2e 3.320 6e No inhibition at
NH2
— 2f 6.020 6f No inhibition at
OH
2g 6.320 6g No inhibition at
1h 44418 2h 1520 6h 10% at 625 lM
1i 1018 2i 0.3520 6i 10% at 625 lM
OBn
— —
O
O
— —
a A Ki value of 2.4 lM was measured independently by N. G. Oikonomakos and co-wo
Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2O
O
F
simple change to the 2-naphthoyl moiety (2i) remarkably
improved the inhibition compared to 2h (43-fold increase) and
more moderately in comparison to the benzoyl derivative 2b
(13-fold increase). The 2-naphthoyl derivative 2i was the ﬁrst glu-
cose-based inhibitor with sub-micromolar activity against GP. In
the series N-acyl-b-D-glucopyranosylamines 1, a similar observa-
tion could be made since the 2-naphthoyl derivative 1i was the
best inhibitor, found much more effective (44-fold) than 1h, with
a regioisomeric 1-naphthoyl residue. Other members of this family
displayed usually weak inhibition with the exception of the acetyl
derivative 1awith a Ki value of 32 lM. The methyl substituted oxa-
diazoles 6a and 7a and acetyl urea 2a showed poor (6a, 2a) or no
detectable (7a) inhibition.
The 3-C-glucosylated 1,2,4-oxadiazoles 7 with a large series of
aromatic substituents displayed the same inhibition pattern with
the 2-naphthyl derivative 7i as the best inhibitor in the series.
The phenyl substituted oxadiazole 7b was a poor inhibitor and
the p-nitrophenyl derivative 7e displayed the worst inhibition in
the series. This detrimental effect exerted by the nitro group was
not observed in the acyl urea series (compare 7e and 2e).
Nevertheless, the biological activity of these 3-C-glucosylatedE
D
P
R
lucopyranosylamines 1a–c,h,i, N-acyl-N0-b-D-glucopyranosyl ureas 2a–c,e–i, 2-(b-D-
d-1,2,4-oxadiazoles 7a–e,h,i and 5-(b-D-glucopyranosyl)-3-substituted-1,2,4-oxadiaz-
R
O
H N
ON
R
O
H N
NO
R
7a No inhibition at 625 lM —
7b 10% at 625 lM23 8b 64
625 lM 7c 350*23 8c 8.8
625 lM 7d 550*23 8d 20.4
625 lM 7e No inhibition at 625 lM 8e 650*
625 lM — 8f 20% at 625 lM
625 lM — 8g 19.4
7h No inhibition at 625 lM 8h 19.0
7i 3823 8i 11.6a
— 8j No inhibition at 625 lM
— 8k >625*
rkers (unpublished results).
009), doi:10.1016/j.bmc.2009.04.036
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Figure 1. Observed and probable orientations of the heterocyclic moieties of
C-glucosyl oxadiazole type inhibitors upon binding to the catalytic site of GP.
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1,2,4-oxadiazoles 7 was always weaker than the corresponding
N-acyl-N0-b-D-glucopyranosyl ureas 2.
The 5-C-glucosylated 1,2,4-oxadiazoles 8 are generally better
inhibitors than the corresponding 3-C-glucosylated counterparts
7 and followed a similar trend with the 2-naphthyl derivative 8i
being among the best (displaying a value very close to the stron-
gest inhibitor 8c) and the p-nitrophenyl 8e the worst in the series.
The weak inhibition observed for the p-benzyloxy-phenyl deriva-
tive 8j might be attributed to the steric hindrance of the benzyl
moiety in comparison to the naphthyl residue and also to the rota-
tion around the methylene benzylic group creating an entropy loss
for the binding process.
Very surprisingly, the 1,3,4-oxadiazoles 6 with a substituent
larger than methyl did not display any meaningful inhibition
against RMGPb. To explain this unexpected result, we propose to
consider the binding peculiarities of these molecules to the active
site of GP as revealed by X-ray crystallography. Because of the lack
of binding of the 1,3,4-oxadiazoles one has to go back to the struc-
ture of the enzyme–inhibitor complex obtained with the methyl-
ated analogue 6a, while an X-ray structure is available for the
enzyme-complex of the 2-naphthyl substituted 8i.25
There are no direct H-bonds between the heterocycle of 6a and
the protein, however, an extensive H-bond network involving
nitrogen atoms N-3 and N-4 exists with the participation of water
molecules.22 As a result, 6a binds in the orientation shown in
Figure 1a. The compound can be accommodated at the catalytic
site with essentially no disturbance of the protein structure. The
relatively small methyl group makes 6 van der Waals interactions
while the b-channel remains unoccupied.
Similarly, no direct H-bonds could be observed between the
heterocycle of 5-glucosyl-1,2,4-oxadiazole 8i and the protein.25
The nitrogen atom N-4 takes part in a H-bond network mediated
by water molecules. Due to the isomeric constitution of the hetero-
cyclic part of this molecule as compared to 6a, the 3-substituent is
in a favorable position to make interactions with residues sur-
rounding the b-channel. The aromatic moiety makes 11 van der
Waals contacts in the b-channel for the 2-naphthyl derivative 8i.
These interactions result in a strong binding with the orientation
of 8i represented by Figure 1d. For the isomeric oxadiazoles 7
(Fig. 1c), a similar interaction pattern and orientation can be postu-
lated. In the case of the 1,3,4-oxadiazole series with large aromatic
substituents (6), interactions in the b-channel would require a
rotameric orientation of the heterocycle as shown in Figure 1b.
However, this conformation would ultimately result in a loss of
participation of N-3 and N-4 in the H-bond network. In the other
orientation (like in Fig. 1a), the accommodation of large substitu-
ents in the vicinity of the catalytic site would most probablyPlease cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2D
P
R
O
O
F
signiﬁcantly disturb the protein structure. These factors together
prevent compounds 6 from strong binding to GP.
3. Conclusion
The synthesis of three series of C-glycosylated oxadiazoles
could be achieved from per-O-benzoylated b-D-glucopyranosyl
cyanide as a common starting material. Its transformation either
into the corresponding 5-(b-D-glucopyranosyl)tetrazole and subse-
quent acylation or into anhydro-aldose acylhydrazones followed
by oxidation furnished 2-(b-D-glucopyranosyl)-5-substituted-
1,3,4-oxadiazoles. 1,3-Dipolar cycloaddition of nitrile oxides to
the cyanide moiety afforded 5-(b-D-glucopyranosyl)-3-substi-
tuted-1,2,4-oxadiazoles. The regioisomeric 3-(b-D-glucopyrano-
syl)-5-substituted-1,2,4-oxadiazoles were prepared previously by
ring closure of intermediate O-acyl-amidoximes.
Enzyme kinetic evaluation of these inhibitors showed that the
nature of the oxadiazole ring attached to C-1 of glucopyranose is
strongly inﬂuencing the inhibitory activity towards RMGPb. While
the 1,3,4-oxadiazoles proved practically inactive, the 1,2,4-oxadiaz-
ole series displayed inhibition in the micromolar range with the 5-
glucosylated derivatives being superior to their 3-glucosylated
regioisomers. The nature of the p-substituent of the phenyl moiety
exhibited a similar inﬂuence on the inhibition of GP in each series.
In addition, the size and orientation of the aromatic substituent of
the oxadiazole strongly modulated the activity. The 2-naphthyl
derivatives in both 1,2,4-oxadiazole series were among the best
inhibitors. A possible explanation was proposed to understand the
differences in the inhibitory strengths of the isomeric oxadiazoles.E
4. Experimental
4.1. General methods
Thin-layer chromatography (TLC) was carried out on aluminum
sheets coated with Silica Gel 60 F254 (Merck). TLC plates were
inspected by UV light (k = 254 nm) and developed by treatment
with a mixture of 10% H2SO4 in EtOH/H2O (1/1 v/v) followed by
heating. Silica gel column chromatography was performed with
Geduran Silica Gel Si 60 (40–63 lm) purchased from Merck
(Darmstadt, Germany). Reversed-phase silica gel column chroma-
tography was performed on a Varian Bond Elut C18 (20 mm,
15 mm diameter). 1H and 13C NMR spectra were recorded at
23 C using Bruker AC200, DRX300, WP 360 SY, or DRX500 spec-
trometers with TMS or the residual solvent as the internal stan-
dard. The following abbreviations are used to explain the
observed multiplicities: s, singlet; d, doublet; dd, doublet of dou-
blet; ddd, doublet of doublet of doublet; t, triplet; td, triplet of dou-
blet; q, quadruplet; m, multiplet; br, broad; p, pseudo. Structure
elucidation was deduced from 1D and 2D NMR spectroscopy which
allowed, in most cases, complete signal assignments based on
COSY, HSQC and HMBC correlations. Atoms in the pyranosyl rings
are numbered by primed ﬁgures and the aryl substituents with
double-primed ﬁgures while those of the oxadiazole ring have
the oxa sufﬁx. NMR solvents were purchased from Euriso-Top
(Saint Aubin, France) or Sigma–Aldrich. HRMS (LSIMS) mass spec-
tra were recorded in the positive mode using a Thermo Finnigan
Mat 95 XL spectrometer. MS (ESI) mass spectra were recorded in
the positive mode using a Thermo Finnigan LCQ spectrometer.
Optical rotations were measured using a Perkin Elmer polarimeter.
Elemental analyses were performed at the Service Central d’Analy-
ses du CNRS (Vernaison, France).
Method A: To a solution of tetrazole 10 (700 mg, 1.08 mmol) in
abs. pyridine (10 mL) the corresponding acid chloride (5.40 mmol)009), doi:10.1016/j.bmc.2009.04.036
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was added. The reaction mixture was stirred at 90 C for 1 h. It was
then cooled to rt, water was added, and extracted with CH2Cl2
(3  40 mL). The combined organic phase was washed with satu-
rated aqueous NaHCO3 solution and water. The organic phase
was dried (MgSO4), concentrated under diminished pressure and
the crude product was puriﬁed by column chromatography (hex-
ane–EtOAc 3:1) and then crystallized from EtOH.
Method B: Perbenzoylated glucopyranosyl-tetrazole 10 was dis-
solved in abs. toluene (100 mg/mL) then acid chloride (1.2–
2 equiv) was added in one portion. The mixture was reﬂuxed and
monitored by TLC. After disappearance of the starting material
the solvent was removed under diminished pressure, the residue
was puriﬁed by column chromatography if necessary and crystal-
lized from EtOH.
Method C: An anhydro-aldose benzoylhydrazone (12 or 14,
0.25 mmol) was dissolved in CH2Cl2 (2.4 mL) and PIDA
(159 mg, 0.50 mmol) was added. The reaction mixture was stir-
red at rt. When the reaction was complete (TLC: EtOAc/hexane,
1:1), the solution was diluted with CH2Cl2 (4 mL) and water
(2 mL). The aqueous layer was extracted with CH2Cl2
(3  4 mL), then the combined organic layers were washed with
cold saturated NaHCO3 solution (1  5 mL), dried (Na2SO4) and
ﬁltered. The solvent was removed by evaporation under dimin-
ished pressure and the residue puriﬁed by column chromatogra-
phy (EtOAc/hexane, 1:2).
Method D: A solution of arylaldehyde (40 mmol), hydroxyl-
amine hydrochloride (80 mmol, 2 equiv) and sodium hydroxide
(80 mmol, 2 equiv) in EtOH (50 mL) was stirred at 78 C for 2 h.
The suspension was ﬁltered and the solid washed with EtOH
(2  20 mL). The ﬁltrate was evaporated and the residue dissolved
in EtOAc (150 mL). The organic layer was washed with water
(3  70 mL), dried (Na2SO4), ﬁltered and evaporated to dryness. A
portion of the crude arylaldoxime (7 mmol) was then dissolved
in DMF (10 mL) and NCS (7 mmol, 1 equiv) was added in 8–10 por-
tions. The reaction was slightly exothermic and NCS portions were
added slowly in order to maintain the temperature at 35–40 C. If
no heat was generated after the ﬁrst two additions of NCS, a stream
of HCl (generated ex situ from NaCl and H2SO4) was bubbled
through the solution in order to start the reaction then stopped
when the temperature reached 35–40 C. The reaction was then
stirred for 3 h at rt and poured into EtOAc (100 mL). The organic
layer was washed with water (3  50 mL), dried (Na2SO4), ﬁltered
and evaporated to dryness. The hydroximoyl chlorides 16b–e,g–k
were used for cycloadditions without further puriﬁcation.
Method E: A solution of glucosyl cyanide 9 (0.5 mmol) and a
hydroximoyl chloride (2.5 mmol, 5 equiv) in toluene (5 mL) was
stirred at 110 C under argon. Triethylamine (3.75 mmol,
7.5 equiv) was dissolved in toluene (5 mL) and slowly added in
12 h with a syringe pump. The reaction was stirred at 110 C
for an additional 12 h then the solvent was evaporated under
diminished pressure. The residue was puriﬁed by ﬂash silica
gel column chromatography to afford the desired 1,2,4-oxadiaz-
oles 17.
Method F: A solution of the acyl-protected carbohydrate deriva-
tives 17 (0.15 mmol) and NaOMe (50 lL, 1 M in MeOH) in MeOH
(3 mL) was stirred at rt for 3 h. The solution was then neutralized
to pH 5 with a cation exchange resin (DOWEX 50WX2, H+ form).
The resin was ﬁltered off and washed with MeOH (3  10 mL) then
the ﬁltrate was evaporated under diminished pressure. The residue
was puriﬁed by ﬂash silica gel column chromatography to afford
the desired carbohydrate derivatives 8.
Method G: The benzoylated compounds 11 were dissolved in a
mixture of abs. MeOH and abs. CHCl3 and 1 M methanolic sodium
methoxide solution was added to the solutions in catalytic amount.
The reaction mixture was kept at room temperature for a given
time and then neutralized with a cation exchange resin AmberlystPlease cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
D
P
R
O
O
F
15 (H+ form). After ﬁltration and removal of the solvent under
diminished pressure, the crude product was puriﬁed by crystalliza-
tion from Et2O or by column chromatography to afford the depro-
tected carbohydrate derivatives 6.
4.2. Synthesis of 5-aryl-2-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-oxadiazoles
4.2.1. 5-(b-D-Glucopyranosyl)-2-phenyl-1,3,4-oxadiazole (6b)
Prepared according to method G. Yield: 91% (white crystals).
Mp = 165–167 C. ½a20D ¼ þ33 (c 0.2, MeOH). 1H NMR (360 MHz,
CD3OD): d = 8.04-7.52 (m, 5H, H-ar) 4.61 (d, 1H, J = 10.6 Hz, H-
10), 3.87 (pdd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a), 3.78 (t, 1H,
J = 9.3 Hz, H-20 or H-30 or H-40), 3.68 (dd, 1H, J = 5.3 Hz,
J = 11.9 Hz, H-60b), 3.53-3.40 (m, 3H, H-20or H-30 or H-40 and H-
50). 13C NMR (90 MHz, CD3OD): d = 166.9, 165.6 (C-2oxa, C-5oxa),
133.5, 130.5, 130.5, 128.1, 128.1, 124.7, 82.9 (C-10), 79.1, 74.7,
73.5, 71.3 (C-20, C-30, C-40, C-50), 62.7 (C-60). Anal. Calcd for
C14H16N2O6 (308.29): C, 54.54; H, 5.23; N, 9.09. Found: C, 54.27;
H, 5.30; N, 8.94.
4.2.2. 5-(b-D-Glucopyranosyl)-2-(4-methylphenyl)-1,3,4-
oxadiazole (6c)
Prepared according to method G. Yield: 83 mg, 67% (white crys-
tals). Mp = 185–188 C. ½a20D ¼ þ19 (c 0.14, H2O). 1H NMR
(360 MHz, D2O): d = 7.77 (d, 2H, J = 7.9 Hz, H-ar), 7.31 (d, 2H,
J = 7.9 Hz, H-ar), 4.72 (d, 1H, J = 10.6 Hz, H-10), 3.92 (pdd, 1H,
J < 1 Hz, J = 11.9, H-60a), 3.86-3.55 (m, 5H, H-20, H-30, H-40, H-50,
H-60b), 2.34 (s, 3H, PhCH3). 13C NMR (90 MHz, D2O): d = 166.8,
164.0 (C-2oxa, C-5oxa), 144.7, 130.5, 127.5, 119.9, 81.2 (C-10),
77.3, 73.2, 72.2, 69.9 (C-20, C-30, C-40, C-50), 61.3 (C-60), 21.4
(PhCH3). Anal. Calcd for C15H18N2O6 (322.32): C, 55.90; H, 5.63;
N, 8.69. Found: C, 55.82; H, 5.55; N, 8.61.
4.2.3. 5-(b-D-Glucopyranosyl)-2-(4-methoxyphenyl)-1,3,4-
oxadiazole (6d)
Prepared according to method G. Yield: 65% (yellowish amor-
phous solid). ½a20D ¼ þ15 (c 0.16, H2O). 1H NMR (360 MHz, D2O):
d = 7.68 (d, 2H, J = 7.9 Hz, H-ar), 6.89 (d, 2H, J = 7.9 Hz, H-ar), 4.71
(d, 1H, J = 9.2 Hz, H-10), 3.95 (pdd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a),
3.86-3.81 (m, 5H, H-20, H-60b, OMe), 3.69-3.64 (m, 2H, H-30, H-
50), 3.57 (t, 1H, J = 9.2 Hz, H-40). 13C NMR (90 MHz, D2O):
d = 166.3, 163.8 (C-2oxa, C-5oxa), 129.4-115.1 (CH-ar, CIV-ar),
81.2 (C-10), 77.5, 73.2, 72.3, 69.9 (C-20, C-30, C-40, C-50), 61.4 (C-
60), 56.1 (OMe). Anal. Calcd for C15H18N2O7 (338.32): C, 53.25; H,
5.36; N, 8.28. Found: C, 53.19; H, 5.30; N, 8.35.
4.2.4. 5-(b-D-Glucopyranosyl)-2-(4-nitrophenyl)-1,3,4-
oxadiazole (6e)
Prepared according to method G. Puriﬁed by column chroma-
tography (CHCl3/MeOH, 9:1) Yield: 76% (yellow crystals).
Mp = 124–126 C. ½a20D ¼ þ22 (c 0.52, DMSO). 1H NMR (360 MHz,
CD3SOCD3): d = 8.44 (d, 2H, J = 9.3 Hz, H-ar), 8.30 (d, 2H,
J = 9.3 Hz, H-ar), 5.44 (d, 1H, J = 5.3 Hz, OH), 5.24 (d, 1H,
J = 4.0 Hz, OH), 5.14 (d, 1H, J = 5.3 Hz, OH), 4.63–4.58 (m, 2H, H-
10, OH), 3.74–3.37 (m, 6H, H-20, H-30, H-40, H-50, H-60a, H-60b). 13C
NMR (90 MHz, CD3SOCD3): d = 164.8, 163.1 (C-2oxa, C-5oxa),
149.3, 128.6, 128.1, 124.7, 81.9 (C-10), 77.2, 72.7, 71.8, 69.9 (C-20,
C-30, C-40, C-50), 61.0 (C-60). Anal. Calcd for C14H15N3O8 (353.29):
C, 47.60; H, 4.28; N, 11.89. Found: C, 47.69; H, 4.34; N, 11.80.
4.2.5. 2-(4-Aminophenyl)-5-(b-D-glucopyranosyl)-1,3,4-
oxadiazole (6f)
Compound 6e (60 mg, 0.17 mmol) was dissolved in a mixture of
abs. EtOAc (2 mL) and abs. MeOH (2 mL), and reduced by H2
(1 atm) using Raney-Ni as catalyst at 60 C for 8 h. After ﬁltration009), doi:10.1016/j.bmc.2009.04.036
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and evaporation of the solvents the residue was puriﬁed by col-
umn chromatography (CHCl3/MeOH, 4:1) Yield: 28 mg, 51% (yel-
lowish crystals). Mp = 215–217 C. ½a20D ¼ þ16 (c 0.12, DMSO). 1H
NMR (360 MHz, CD3SOCD3): d = 7.68 (d, 2H, J = 7.9 Hz, H-ar), 6.70
(d, 2H, J = 7.9 Hz, H-ar), 5.98 (s, 2H, NH2), 5.39 (d, 1H, J = 5.3 Hz,
OH), 5.21 (d, 1H, J = 5.3 Hz, OH), 5.13 (d, 1H, J = 5.3 Hz, OH), 4.64
(dd, 1H, J = 6.6 Hz, J = 5.3 Hz, OH), 4.47 (d, 1H, J = 9.3 Hz, H-10),
3.74-2.20 (m, 6H, H-20, H-30, H-40, H-50, H-60a, H-60b). 1H NMR
(360 MHz, CD3OD): d = 7.74 (d, 2H, J = 9.3 Hz, H-ar), 6.74 (d, 2H,
J = 9.3 Hz, H-ar), 4.57 (d, 1H, J = 9.3 Hz, H-10), 3.89 (pdd, 1H,
J < 1 Hz, J = 10.6 Hz, H-60a), 3.79 (t, 1H, J = 9.3 Hz, H-20), 3.70 (dd,
1H, J = 4.0 Hz, J = 11.9 Hz, H-60b), 3.54-3.34 (m, 3H, H-30, H-40,
H-50). 13C NMR (90 MHz, CD3OD): d = 167.8, 164.3 (C-2oxa, C-
5oxa), 154.1, 129.7, 115.2, 111.7, 82.9 (C-10), 79.2, 74.7, 73.4,
71.3 (C-20, C-30, C-40, C-50), 62.7 (C-60). Anal. Calcd for C14H17N3O6
(323.31): C, 52.01; H, 5.30; N, 13.00. Found: C, 50.94; H, 5.22; N,
13.10.
4.2.6. 5-(b-D-Glucopyranosyl)-2-(4-hydroxyphenyl)-1,3,4-
oxadiazole (6g)
Prepared according to method G. Yield: 45% (yellowish amor-
phous solid). ½a20D ¼ þ20 (c 0.2, MeOH). 1H NMR (360 MHz, D2O):
d = 7.84 (d, 2H, J = 7.9 Hz, H-ar), 6.97 (d, 2H, J = 7.9 Hz, H-ar), 3.98
(pdd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a), 3.91-3.79 (m, 3H, H-10, H-20,
H-60b), 3.73-3.68 (m, 2H, H-30, H-50), 3.60 (t, 1H, J = 9.2 Hz, H-40).
13C NMR (90 MHz, D2O): d = 163.7, 160.4 (C-2oxa, C-5oxa), 129.9-
114.9 (CH-ar, CIV-ar), 81.1 (C-10), 77.3, 73.2, 72.2, 69.9 (C-20, C-30,
C-40, C-50), 61.4 (C-60). Anal. Calcd for C14H16N2O7 (324.29): C,
51.85; H, 4.97; N, 8.64. Found: C, 51.79; H, 4.91; N, 8.71.
4.2.7. 5-(b-D-Glucopyranosyl)-2-(1-naphthyl)-1,3,4-oxadiazole (6h)
Prepared according to method G. Yield: 91% (colorless syrup).
½a20D ¼ þ35 (c 0.2, MeOH). 1H NMR (360 MHz, CD3OD): d = 8.96–
7.50 (m, 7H, H-ar), 4.69 (d, 1H, J = 10.6 Hz, H-10), 3.91–3.82 (m,
2H, H-20 or H-30 or H-40 and H-60a), 3.70 (dd, 1H, J = 5.3 Hz,
J = 11.9 Hz, H-60b), 3.57–3.44 (m, 3H, H-20 or H-30 or H-40 and H-
50). 13C NMR (90 MHz, CD3OD): d = 166.7, 165.3 (C-2oxa, C-5oxa),
135.3, 134.1, 131.2, 130.0, 130.0, 129.2, 127.9, 126.6, 126.1,
121.1, 82.9 (C-10), 79.1, 74.7, 73.6, 71.3 (C-20, C-30, C-40, C-50),
62.7 (C-60). Anal. Calcd for C18H18N2O6 (358.35): C, 60.33; H,
5.06; N, 7.82. Found: C, 60.22; H, 5.30; N, 7.98.
4.2.8. 5-(b-D-Glucopyranosyl)-2-(2-naphthyl)-1,3,4-oxadiazole (6i)
Prepared according to method G. Yield: 96% (white crystals).
Mp = 219–221 C. ½a20D ¼ 5 (c 0.1, DMSO). 1H NMR (360 MHz,
CD3SOCD3): d = 8.66–7.66 (m, 7H, H-ar), 5.49 (d, 1H, J = 9.2 Hz, H-
10), 3.72–3.16 (m, 6H, H-20, H-30, H-40, H-50, H-60a, H-60b). 13C
NMR (90 MHz, CD3SOCD3): d = 164.6, 164.0 (C-2oxa, C-5oxa),
134.2, 132.4, 129.3, 128.9, 128.3, 127.9, 127.3, 127.1, 122.8,
120.4, 81.9 (C-10), 77.3, 72.7, 71.7, 69.9 (C-20, C-30, C-40, C-50),
61.0 (C-60). Anal. Calcd for C18H18N2O6 (358.35): C, 60.33; H,
5.06; N, 7.82. Found: C, 60.23; H, 5.18; N, 7.65.
4.3. Synthesis of 3-aryl-5-(b-D-glucopyranosyl)-1,3,4-oxadiazoles
4.3.1. 5-(b-D-Glucopyranosyl)-3-phenyl-1,2,4-oxadiazole (8b)
and 5-(2-deoxy-D-arabino-hex-1-enopyranosyl)-3-phenyl-1,2,4-
oxadiazole (18b)
A solution of 17b (155 mg, 0.21 mmol) was treated according to
method F. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 3:2 then EtOAc then EtOAc/MeOH 9:1) to
afford 8b (67 mg, 92%) as a yellow solid and 18b (5 mg, 8%) as a
yellow solid. Analytical data for 8b: Rf = 0.41 (EtOAc /MeOH, 9:1).
Mp = 129–130 C (MeOH/hexane). ½a20D ¼ þ16 (c 1, MeOH). 1H
NMR (300 MHz, CD3OD): d = 8.10–8.06 (m, 2H, H-ar), 7.55–7.50
(m, 3H, H-ar), 4.66 (d, 1H, J = 9.8 Hz, H-10), 3.91 (pdd, 1H, J < 1 Hz,Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
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J = 12.2 Hz, H-60a), 3.80 (dd, 1H, J = 8.5 Hz, J = 9.8 Hz, H-20), 3.72
(dd, 1H, J = 4.5 Hz, J = 12.2 Hz, H-60b), 3.50–3.40 (m, 3H, H-30, H-
40, H-50). 13C NMR (75 MHz, CD3OD): d = 178.2 (C-5oxa), 169.6 (C-
3oxa), 132.6, 130.1 (2C), 128.4 (2C), 127.8 (CIV-ar), 83.0 (C-50),
79.2 (C-30), 75.1 (C-10), 74.0 (C-20), 71.2 (C-40), 62.7 (C-60). MS
(LSIMS, glycerol) m/z = 309 [M+H]+. HRMS (LSIMS, glycerol) m/
z = C14H17N2O6 [M+H]+ calcd 309.1087, found 309.1088. Analytical
data for 18b: Rf = 0.51 (EtOAc/MeOH, 9:1). 1H NMR (300 MHz,
CD3OD): d = 8.10–7.96 (m, 5H, H-ar), 6.13 (d, 1H, J = 2.8 Hz, H-20),
4.34 (dd, 1H, J = 2.8 Hz, J = 7.2 Hz, H-30), 4.06 (ddd, 1H, J = 2.3 Hz,
J = 5.2 Hz, J = 9.5 Hz, H-50), 4.01 (dd, 1H, J = 2.3 Hz, J = 12.6 Hz, H-
60a), 3.93 (dd, 1H, J = 5.2 Hz, J = 12.6 Hz, H-60b), 3.75 (dd,
J = 7.2 Hz, J = 9.5 Hz, H-40). 13C NMR (75 MHz, CD3OD): d = 172.9
(C-5oxa), 169.8 (C-3oxa), 141.1 (C-10), 132.7, 130.7, 128.4, 127.7
(CIV-ar), 112.9 (C-20), 82.3 (C-50), 70.2 (C-30), 69.7 (C-40), 61.9 (C-
60). MS (LSIMS, glycerol) m/z = 291 [M+H]+. HRMS (LSIMS, glycerol)
m/z = C14H15N2O5 [M+H]+ calcd 291.0981, found 291.0981.
4.3.2. 5-(b-D-Glucopyranosyl)-3-(4-methylphenyl)-1,2,4-oxadi-
azole (8c) and 5-(2-deoxy-D–D-arabino-hex-1-enopyranosyl)-3-
(4-methylphenyl)-1,2,4-oxadiazole (18c)
A solution of 17c (250 mg, 0.38 mmol) was treated according to
method F. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 3:2 then EtOAc then EtOAc/MeOH 9:1) to
afford 8c (103 mg, 92%) as a colorless oil and 18c (11 mg, 8%) as
a colorless oil. Analytical data for 8c: Rf = 0.38 (EtOAc/MeOH,
9:1). ½a20D ¼ þ14 (c 1, MeOH). 1H NMR (300 MHz, CD3OD):
d = 7.74 (d, 2H, J = 8.1 Hz, H-ar), 7.34 (d, 2H, J = 8.1 Hz, H-ar), 4.64
(d, 1H, J = 9.8 Hz, H-10), 3.90 (pdd, 1H, J < 1 Hz, J = 12.3 Hz, H-60a),
3.78 (dd, 1H, J = 8.6 Hz, J = 9.8 Hz, H-20), 3.71 (dd, 1H, J = 5.3 Hz,
J = 12.3 Hz, H-60b), 3.55-3.45 (m, 3H, H-30, H-40, H-50), 2.41 (s, 3H,
CH3Ph). 13C NMR (75 MHz, CD3OD): d = 178.1 (C-5oxa), 169.6 (C-
3oxa), 143.3 (C-100), 130.8 (2C, C-200, C-600), 128.4 (2C, C-300, C-500),
125.0 (C-400), 83.0 (C-50), 79.2 (C-30), 75.2 (C-10), 74.0 (C-20), 71.3
(C-40), 62.8 (C-60), 21.6 (CH3Ph). MS (ESI) m/z = 323.0 [M+H]+,
345.1 [M+Na]+, 666.9 [2 M+Na]+. HRMS (ESI) m/z = C15H19N2O6
[M+H]+ calcd 323.1243, found 323.1245. Analytical data for 18c:
Rf = 0.38 (EtOAc/MeOH, 9:1). 1H NMR (300 MHz, CD3OD): d = 7.94
(d, 2H, J = 8.1 Hz, H-ar), 7.34 (d, 2H, J = 8.1 Hz, H-ar), 6.12 (d, 1H,
J = 2.8 Hz, H-20), 4.33 (dd, 1H, J = 2.8 Hz, J = 7.2 Hz, H-30), 4.06
(ddd, 1H, J = 2.6 Hz, J = 5.4 Hz, J = 9.5 Hz, H-50), 4.01 (m, 1H, H-
60a), 3.94 (dd, 1H, J = 5.4 Hz, J = 12.6 Hz, H-60b), 3.75 (dd,
J = 7.2 Hz, J = 9.5 Hz, H-40), 2.41 (s, 3H, CH3Ph). 13C NMR (75 MHz,
CD3OD): d = 172.8 (C-5oxa), 169.9 (C-3oxa), 143.4 (C-10), 141.2,
130.8 (2C), 128.4 (2C), 124.9 (CIV-ar), 112.8 (C-20), 82.3 (C-50),
70.3 (C-30), 69.8 (C-40), 62.0 (C-60), 21.6 (CH3Ph). MS (ESI) m/
z = 304.8 [M+H]+, 327.0 [M+Na]+, 630.8 [2M+Na]+. HRMS (ESI) m/
z = C15H17N2O5 [M+H]+ calcd 305.1137, found 305.1136.
4.3.3. 5-(b-D-Glucopyranosyl)-3-(4-methoxyphenyl)-1,2,4-oxadi-
azole (8d) and 5-(2-deoxy-D-arabino-hex-1-enopyranosyl)-3-(4-
methoxyphenyl)-1,2,4-oxadiazole (18d)
A solution of 17d (187 mg, 0.25 mmol) was treated according to
method F. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 3:2 then EtOAc then EtOAc/MeOH 9:1) to
afford 8d (62 mg, 75%) as a white solid and 18d (3 mg, 5%) as a pale
yellow solid. Analytical data for 8d: Rf = 0.08 (EtOAc). Mp = 152–
153 C (MeOH/hexane). ½a20D ¼ þ16 (c 0.75, MeOH). 1H NMR
(300 MHz, CD3OD): d = 8.00 (d, 2H, J = 8.9 Hz, H-ar), 7.05 (d, 2H,
J = 8.9 Hz, H-ar), 4.63 (d, 1H, J = 9.6 Hz, H-10), 3.91 (pdd, 1H,
J < 1 Hz, J = 12.3 Hz, H-60a), 3.86 (s, 3H, OCH3), 3.79 (dd, 1H,
J = 8.8 Hz, J = 9.6 Hz, H-20), 3.72 (dd, 1H, J = 4.8 Hz, J = 12.3 Hz, H-
60b), 3.50-3.43 (m, 3H, H-30, H-40, H-50). 13C NMR (75 MHz, CD3OD):
d = 177.9 (C-5oxa), 169.3 (C-3oxa), 163.8 (C-40 0), 130.1 (2C), 120.0
(CIV-ar), 115.2 (2C), 83.0 (C-5), 79.2 (C-30), 75.2 (C-10), 74.0 (C-20),
71.2 (C-40), 62.8 (C-60), 56.0 (OCH3). MS (LSIMS, glycerol) m/z = 339009), doi:10.1016/j.bmc.2009.04.036
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[M+H]+. HRMS (LSIMS, glycerol) m/z = C15H19N2O7 [M+H]+ calcd
339.1192, found 339.1191. Analytical data for 18d: Rf = 0.17
(EtOAc). 1H NMR (500 MHz, CD3OD): d = 8.00 (d, 2H, J = 8.9 Hz, H-
ar), 7.07 (d, 2H, J = 8.9 Hz, H-ar), 6.11 (d, 1H, 1H, J = 2.8 Hz, H-20),
4.34 (dd, 1H, J = 2.8 Hz, J = 7.3 Hz, H-30), 4.06 (ddd, 1H, J = 2.3 Hz,
J = 5.4 Hz, J = 9.5 Hz, H-50), 4.03 (dd, 1H, J = 2.3 Hz, J = 12.7 Hz, H-
60a), 3.93 (dd, 1H, J = 5.4 Hz, J = 12.7 Hz, H-60b), 3.87 (s, 3H, OCH3),
3.74 (dd, J = 7.3 Hz, J = 9.5 Hz, H-40). 13C NMR (125 MHz, CD3OD):
d = 171.6 (C-5oxa), 168.5 (C-3oxa), 162.9 (C-40 0), 140.1 (C-10), 129.0
(2C), 118.8 (CIV-ar), 114.5 (2C), 111.7 (C-20), 81.2 (C-50), 69.2 (C-30),
68.7 (C-40), 60.9 (C-60), 54.9 (OCH3). MS (LSIMS, glycerol)m/z = 321
[M+H]+. HRMS (LSIMS, glycerol) m/z = C15H17N2O6 [M+H]+ calcd
321.1087, found 321.1087.
4.3.4. 5-(b-D-Glucopyranosyl)-3-(4-nitrophenyl)-1,2,4-oxadiazole
(8e) and 5-(2-deoxy-D-arabino-hex-1-enopyranosyl)-3-(4-nitro-
phenyl)-1,2,4-oxadiazole (18e)
A solution of 17e (258 mg, 0.34 mmol) was treated according to
method F. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 3:2 then EtOAc then EtOAc/MeOH 9:1) to
afford 8e (89 mg, 76%) as a yellow solid and 18e (4 mg, 4%) as a yel-
low solid. Analytical data for 8e: Rf = 0.08 (EtOAc). Mp = 141–
142 C (MeOH/hexane). ½a20D ¼ þ22 (c 0.5, MeOH). 1H NMR
(300 MHz, CD3OD): d = 8.43–8.36 (m, 2H, H-ar), 8.34–8.30 (m,
2H, H-ar), 4.70 (d, 1H, J = 9.8 Hz, H-10), 3.92 (dd, 1H, J = 1.7 Hz,
J = 12.0 Hz, H-60a), 3.81 (dd, 1H, J = 9.8 Hz, J = 8.8 Hz, H-20), 3.72
(dd, 1H, J = 5.4 Hz, J = 12.0 Hz, H-60b), 3.54 (dd, 1H, J = 8.5 Hz,
J = 8.8 Hz, H-30), 3.49-3.42 (m, 2H, H-40, H-50). 13C NMR (75 MHz,
CD3OD): d = 178.9 (C-5oxa), 168.3 (C-3oxa), 151.1 (CIV-ar), 133.6
(CIV-ar), 129.6 (2C), 125.3 (2C), 83.1 (C-50), 79.1 (C-30), 75.1 (C-10),
73.9 (C-20), 71.2 (C-40), 62.8 (C-60). MS (LSIMS, glycerol) m/z = 354
[M+H]+. HRMS (LSIMS, glycerol) m/z = C14H16N3O8 [M+H]+ calcd
354.0937, found 354.0940. Analytical data for 18e: Rf = 0.17
(EtOAc). 1H NMR (500 MHz, CD3OD): d = 8.43–8.37 (m, 2H, H-ar),
8.34–8.30 (m, 2H, H-ar), 6.18 (d, 1H, J = 2.8 Hz, H-20), 4.35 (dd,
1H, J = 2.8 Hz, J = 7.3 Hz, H-30), 4.07 (ddd, 1H, J = 1.9 Hz, J = 4.7 Hz,
J = 9.5 Hz, H-50), 4.03 (dd, 1H, J = 1.9 Hz, J = 12.3 Hz, H-60a), 3.95
(dd, 1H, J = 4.7 Hz, J = 12.3 Hz, H-60b), 3.77 (dd,1H, J = 7.3 Hz,
J = 9.5 Hz, H-40). 13C NMR (125 MHz, CD3OD): d = 173.6 (C-5oxa),
168.5 (C-3oxa), 151.2 (CIV-ar), 141.1 (C-10), 133.6 (CIV-ar), 129.6,
125.3 (2C), 113.4 (C-20), 82.3 (C-50), 70.2 (C-30), 69.6 (C-40), 61.8
(C-60). MS (ESI) m/z = 692.7 [2 M+Na]+. HRMS (ESI) m/z = C14H14-
N3O7 [M+H]+ calcd 336.0832, found 336.0836.
4.3.5. 3-(4-Aminophenyl)-5-(b-D-glucopyranosyl)-1,2,4-
oxadiazole (8f)
A solution of 8e (30 mg, 8.2 lmol) and Pd–C 10% (5 mg) in
MeOH (5 mL) was stirred at rt under H2 (1 atm.). After 24 h, the
solution was ﬁltered through a pad of Celite, washed with MeOH
(3  10 mL). The ﬁltrate was evaporated under diminished pres-
sure and the residue was puriﬁed by reversed-phase silica gel col-
umn chromatography (water) to afford 8f (30 mg, 99%) as a pale
brown foam. ½a20D ¼ 7:8 (c 0.95, MeOH). 1H NMR (300 MHz,
CD3OD): d = 7.57 (d, 2H, J = 9.2 Hz, H-200, H-600), 6.73 (d, 2H,
J = 9.2 Hz, H-300, H-500), 3.85 (m, 1H, H-60a), 3.63 (m, 1H, H-60b),
3.56 (m, 1H, H-10), 3.20–3.42 (m, 4H, H-20, H-30, H-40, H-50). 13C
NMR (75 MHz, CD3OD): d = 176.8 (C-5oxa), 166.1 (C-3oxa), 155.1
(C-400), 129.8 (C-200, C-600), 113.7 (C-300, C-500), 113.5 (C-100), 77.7 (C-
10), 80.0, 78.4, 72.7, 70.8 (C-20, C-30, C-40, C-50), 62.0 (C-60).
4.3.6. 5-(b-D-Glucopyranosyl)-3-(4-hydroxyphenyl)-1,2,4-
oxadiazole (8g)
A solution of 17g (173 mg, 0.27 mmol) and NaOMe (5 mg) in
MeOH/CH2Cl2 (10 mL, 9:1) was stirred at rt for 24 h. The reaction
was neutralized to pH 5–6 with Amberlite IR-120 resin (H+ form)
and the resin washed with MeOH (3  10 mL). The ﬁltrate wasPlease cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
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evaporated under diminished pressure and the residue was puri-
ﬁed by ﬂash silica gel column chromatography (PE/EtOAc, 1:1 then
EtOAc then EtOAc/MeOH 95:5) to afford 8g (32 mg, 37%) as a white
gum. Rf = 0.39 (EtOAc/MeOH, 85:15). ½a20D ¼ þ10:4 (c 1, MeOH). 1H
NMR (300 MHz, CD3OD): d = 7.88 (d, 2H, J = 8.7 Hz, H-200, H-600),
6.88 (d, 2H, J = 8.7 Hz, H-300, H-500), 4.60 (d, 1H, J = 9.9 Hz, H-10),
3.88 (pdd, 1H, J < 1 Hz, J = 11.7 Hz, H-60a), 3.77 (dd, 1H, J = 8.7 Hz,
J = 9.9 Hz, H-20), 3.70 (m, 1H, H-60b), 3.54–3.44 (m, 3H, H-30, H-40,
H-50). 13C NMR (75 MHz, CD3OD): d = 176.7 (C-5oxa), 168.4 (C-
3oxa), 160.8 (C-400), 129.1 (C-200, C-600), 117.7 (C-100), 115.8 (C-300,
C-500), 74.1 (C-10), 72.9 (C-20), 81.9, 78.1, 70.2 (C-30, C-40, C-50),
61.7 (C-60). MS (ESI) m/z = 347.0 [M+Na]+. HRMS (ESI) m/z =
C14H16N2O7 [M+Na]+ calcd 347.0855, found 347.0857.
4.3.7. 5-(b-D-Glucopyranosyl)-3-(1-naphthyl)-1,2,4-oxadiazole (8h)
A solution of 17h (388 mg, 0.43 mmol) and NaOMe (5 mg) in
MeOH/CH2Cl2 (10 mL, 9:1) was stirred at rt for 24 h. The reaction
was neutralized to pH 5–6 with Amberlite IR-120 resin (H+ form)
and the resin washed with MeOH (3  10 mL). The ﬁltrate was
evaporated under diminished pressure and the residue was puri-
ﬁed by ﬂash silica gel column chromatography (PE/EtOAc, 1:1 then
EtOAc then EtOAc/MeOH 95:5) to afford 8h (125 mg, 79%) as a
white solid. Rf = 0.45 (EtOAc/MeOH, 9:1). Mp = 182–183 C.
½a20D ¼ þ14:0 (c 1, MeOH). 1H NMR (500 MHz, CD3OD): d = 8.83
(d, 1H, J = 8.4 Hz, H-800), 8.24 (d, 1H, J = 7.1 Hz, H-200), 8.09 (d, 1H,
J = 8.2 Hz, H-400), 7.99 (d, 1H, J = 7.9 Hz, H-500), 7.65–7.58 (m, 3H,
H-300, H-600, H-700), 4.73 (d, 1H, J = 9.8 Hz, H-10), 3.92 (dd, 1H,
J < 1 Hz, J = 11.7 Hz, H-60a), 3.85 (dd, 1H, J = 9.2 Hz, J = 9.8 Hz, H-
20), 3.74 (dd, 1H, J = 5.4 Hz, J = 11.7 Hz, H-60b), 3.57–3.47 (m, 3H,
H-30, H-40, H-50). 13C NMR (125 MHz, CD3OD): d = 176.4 (C-5oxa),
168.9 (C-3oxa), 134.4 (C-100), 132.1 (C-400), 130.8 (C-8a00), 129.4 (C-
200), 128.8 (C-500), 127.6 (C-600), 126.5 (C-700), 126.0 (C-800), 125.1
(C-300), 123.7 (C-4a00), 82.0, 78.2 (C-30, C-50), 74.2 (C-10), 73.0 (C-
20), 70.2 (C-40), 61.7 (C-60). MS (ESI) m/z = 381.2 [M+Na]+. HRMS
(ESI) m/z = C18H18N2O6 [M+Na]+ calcd 381.1062, found 381.1062.
4.3.8. 5-(b-D-Glucopyranosyl)-3-(2-naphthyl)-1,2,4-oxadiazole
(8i) and 5-(2-deoxy-D-arabino-hex-1-enopyranosyl)-3-(2-
naphthyl)-1,2,4-oxadiazole (18i)
A solution of 17i (340 mg, 0.44 mmol) was treated according to
method F. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 3:2 then EtOAc then EtOAc/MeOH9:1) to af-
ford8i (119 mg, 76%) as a yellow foamand18i (11 mg, 8%) as awhite
solid. Analyticaldata for8i:Rf = 0.51 (EtOAc/MeOH,9:1). ½a20D ¼ þ14
(c 1, MeOH). 1H NMR (300 MHz, CD3OD): d = 8.62 (s, 1H, H-ar), 8.99
(d, 1H, J = 8.6 Hz, H-ar), 7.98–7.92 (m, 3H, H-ar), 7.59–7-55 (m, 2H,
H-ar), 4.70 (d, 1H, J = 9.8 Hz, H-10), 3.93 (pdd, 1H, J < 1 Hz,
J = 12.2 Hz, H-60a), 3.84 (dd, 1H, J = 8.9 Hz, J = 9.8 Hz, H-20), 3.74
(dd, 1H, J = 4.5 Hz, J = 12.2 Hz, H-60b), 3.59–3.49 (m, 3H, H-30, H-40,
H-50). 13C NMR (75 MHz, CD3OD): d = 178.3 (C-5oxa), 169.7 (C-
3oxa), 136.2 (CIV-ar), 134.5 (CIV-ar), 130.0, 129.9, 129.01, 128.98,
128.9, 128.1, 125.1 (CIV-ar), 124.6, 83.0 (C-50), 79.2 (C-30), 75.2 (C-
10), 74.0 (C-20), 71.3 (C-40), 62.8 (C-60). MS (ESI)m/z = 359.0 [M+H]+,
381.0 [M+Na]+, 738.9 [2M+Na]+. HRMS (ESI) m/z = C18H19N2O6
[M+H]+ calcd 359.1243, found 359.1244. Analytical data for 18i:
Rf = 0.61 (EtOAc/MeOH, 9:1). 1H NMR (300 MHz, CD3OD): d = 8.61
(s, 1H, H-ar), 8.10 (dd, 1H, J = 1.6 Hz, J = 8.6 Hz, H-ar), 8.03–7.97
(m, 3H H-ar), 7.61–7.57 (m, 2H, H-ar), 6.16 (d, 1H, J = 2.8 Hz, H-20),
4.36 (dd, 1H, J = 2.8 Hz, J = 7.2 Hz, H-30), 4.09–4.05 (m, 2H, H-50, H-
60a), 3.95 (dd, 1H, J = 5.3 Hz, J = 12.5 Hz, H-60b), 3.77 (dd, 1H,
J = 7.2 Hz, J = 9.5 Hz, H-40). 13C NMR (75 MHz, CD3OD): d = 173.0
(C-5oxa), 169.9 (C-3oxa), 141.2 (C-10), 136.3 (CIV-ar), 134.5 (CIV-ar),
130.1, 129.9, 129.02, 128.96, 128.2, 125.0 (CIV-ar), 124.6, 113.0 (C-
20), 82.3 (C-50), 70.3 (C-30), 69.8 (C-40), 62.0 (C-60). MS (ESI) m/z =
341.0 [M+H]+, 363.0 [M+Na]+, 702.9 [2M+Na]+. HRMS (ESI) m/z =
C18H17N2O5 [M+H]+ calcd 341.1137, found 341.1136.009), doi:10.1016/j.bmc.2009.04.036
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4.3.9. 3-(4-Benzyloxyphenyl)-5-(b-D-glucopyranosyl)-1,2,4-
oxadiazole (8j)
A solution of 17j (205 mg, 0.25 mmol) and NaOMe (5 mg) in
MeOH/CH2Cl2 (5 mL, 9:1) was stirred at rt for 24 h. The reaction
was neutralized to pH 5–6 with Amberlite IR-120 resin (H+ form)
and the resin washed with MeOH (3  10 mL). The ﬁltrate was
evaporated under diminished pressure and the residue was puri-
ﬁed by ﬂash silica gel column chromatography (PE/EtOAc, 1:1 then
EtOAc then EtOAc/MeOH 95:5) to afford 8j (57 mg, 56%) as a white
foam. Rf = 0.31 (EtOAc/MeOH, 9:1). ½a20D ¼ þ10:5 (c 1.13, MeOH).
1H NMR (300 MHz, CD3OD): d = 8.00 (d, 2H, J = 9.0 Hz, H-200, H-
600), 7.50–7.25 (m, 5H, CH2Ph), 7.13 (d, 2H, J = 9.0 Hz, H-300, H-500),
5.15 (s, 2H, CH2Ph), 4.63 (d, 1H, J = 9.6 Hz, H-10), 3.91 (pdd, 1H,
J < 1 Hz, J = 11.4 Hz, H-60a), 3.80 (dd, 1H, J = 8.7 Hz, J = 9.6 Hz, H-
20), 3.72 (m, 1H, H-60b), 3.47 (m, 3H, H-30, H-40, H-50). 13C NMR
(75 MHz, CD3OD): d = 177.9 (C-5oxa), 169.3 (C-3oxa), 162.8 (C-
400), 138.2 (CIV-ar), 130.0 (C-200, C-600), 129.6, 129.0, 128.6 (CH2Ph),
120.3 (C-100), 116.4 (C-300, C-500), 75.1 (C-10), 73.9 (C-20), 83.0, 79.2,
71.2 (C-30, C-40, C-50), 71.1 (CH2Ph), 62.7 (C-60). MS (ESI) m/z =
437.2 [M+Na]+. HRMS (ESI) m/z = C21H22N2O7 [M+Na]+ calcd
437.1325, found 437.1325.
4.3.10. 3-(1,3-Benzodioxol-5-yl)-5-(b-D-glucopyranosyl)-1,2,4-
oxadiazole (8k)
A solution of 17k (280 mg, 0.36 mmol) and NaOMe (5 mg) in
MeOH/CH2Cl2 (15 mL, 2:1) was stirred at rt for 2 h. The reaction
was neutralized to pH 5–6 with Amberlite IR-120 resin (H+ form)
and the resin washed with MeOH (2  10 mL). The ﬁltrate was
evaporated under diminished pressure and the residue was puri-
ﬁed by ﬂash silica gel column chromatography (PE/EtOAc, 1:1
then EtOAc then EtOAc/MeOH 85:15) to afford 8k (74 mg, 60%)
as a pale yellow foam. Rf = 0.41 (EtOAc/MeOH, 85:15).
½a20D ¼ þ18:0 (c 1, DMSO). 1H NMR (300 MHz, CD3OD): d = 7.64
(dd, 1H, J = 1.6 Hz, J = 8.1 Hz, H-500), 7.48 (d, 1H, J = 1.6 Hz, H-
300), 6.95 (d, 1H, J = 8.1 Hz, H-600), 6.05 (s, 2H, OCH2O), 4.62 (d,
1H, J = 9.8 Hz, H-10), 3.91 (dd, 1H, J = 1.6 Hz, J = 12.2 Hz, H-60a),
3.78 (t, 1H, J = 9.8 Hz, H-20), 3.71 (dd, 1H, J = 5.2 Hz, J = 12.2 Hz,
H-60b), 3.56–3.40 (m, 3H, H-30, H-40, H-50). 13C NMR (75 MHz,
CD3OD): d = 178.0 (C-5oxa), 169.3 (C-3oxa), 152.0, 149.8 (C-100,
C-200), 123.4 (C-500), 121.5 (CIV-ar), 109.7 (C-600), 108.7 (C-300),
103.3 (OCH2O), 75.2 (C-10), 74.0 (C-20), 83.0, 79.2, 71.2 (C-30, C-
40, C-50), 62.8 (C-60). MS (ESI) m/z = 353 [M+H]+, 375 [M+Na]+,
727 [2 M+Na]+. HRMS (ESI) m/z = C15H16N2NaO8 [M+Na]+ calcd
375.0804, found 375.0802.
4.4. Zemplén deacylation of 1,3,4-oxadiazoles
4.4.1. 2-Phenyl-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-
1,3,4-oxadiazole (11b)
Prepared according to method A. Yield: 78% (white solid).
Alternative preparation: To a solution of benzoic acid (19 mg,
0.15 mmol) and DCC (32 mg, 0.15 mmol) in abs. toluene was
added tetrazole 10 (100 mg, 0.15 mmol), and reﬂuxed for 4 h.
After cooling to rt the mixture was ﬁltered and evaporated.
The product 11b was crystallized from EtOH (62 mg, 56%) and
obtained as white crystals. Mp = 186–187 C. ½a20D ¼ 195 (c
0.21, CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.06–7.26 (m, 25H,
H-ar), 6.11, 6.01, 5.88 (3  pt, 3H, J  9.3 Hz, H-20, H-30, H-40),
5.29 (d, 1H, J = 9.3 Hz, H-10), 4.71 (dd, 1H, J = 2.6 Hz, J = 11.9 Hz,
H-60a), 4.54 (dd, 1H, J = 5.3 Hz, J = 11.9 Hz, H-60b), 4.40 (ddd,
1H, J = 2.6 Hz, J = 5.3 Hz, J = 9.3 Hz, H-50). 13C NMR (90 MHz,
CDCl3): d = 166.0, 165.9 165.6, 165.1, 164.8 (C@O, C-5oxa),
162.0 (C-2oxa), 133.5–123.3 (CH-ar, CIV-ar), 77.1 (C-10), 73.6,
71.9, 70.3, 69.0 (C-20, C-30, C-40, C-50), 63.0 (C-60). Anal. Calcd
for C42H32N2O10 (724.73): C, 69.61; H, 4.45; N, 3.87. Found: C,
69.52; H, 4.11; N, 3.99.Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
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4.4.2. 2-(4-Methylphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-oxadiazole (11c)
To a solution of tetrazole 10 (500 mg, 0.77 mmol) in abs. tolu-
ene (5 mL) was added 4-methyl-benzoyl chloride (0.95 mmol).
The reaction mixture was reﬂuxed for 3 h then evaporated in vac-
uum. Crystallisation from EtOH gave 11c (379 mg, 70%) as white
crystals. Mp = 170–172 C. ½a20D ¼ 200 (c 0.19, CHCl3). 1H NMR
(360 MHz, CDCl3): d = 8.05–7.80 (m, 10H, H-ar), 7.57–7.29 (m,
14H, H-ar), 6.10 (t, 1H, J = 9.3 Hz, H-20), 6.02 (t, 1H, J = 9.3 Hz, H-
30), 5.87 (dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-40), 5.27 (d, 1H,
J = 9.3 Hz, H-10), 4.70 (dd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a), 4.54
(dd, 1H, J = 5.3 Hz, J = 11.9 Hz, H-60b), 4.38 (ddd, 1H, J < 1 Hz,
J = 5.3 Hz, J = 10.6 Hz, H-50), 2.41 (s, 3H, PhCH3). 13C NMR
(90 MHz, CDCl3): d = 166.1, 165.7, 165.2, 164.9 (C@O), 160.7,
142.7 (C-2oxa, C-5oxa), 133.6–120.6 (CH-ar, CIV-ar), 77.0 (C-10),
73.7, 71.9, 70.2, 69.1 (C-20, C-30, C-40, C-50), 63.0 (C-60), 21.6
(PhCH3). Anal. Calcd for C43H34N2O10 (738.76): C, 69.91; H, 4.64;
N, 3.79. Found: C, 69.99; H, 4.57; N, 3.72.
4.4.3. 2-(4-Methoxyphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-oxadiazole (11d)
To a solution of tetrazole 10 (500 mg, 0.77 mmol) in abs. tolu-
ene (5 mL) was added 4-methoxy-benzoyl chloride (1.54 mmol).
The reaction mixture was reﬂuxed for 1 h. Then it was cooled to
rt, washed with saturated aqueous NaHCO3 solution and water.
The organic phase was dried (MgSO4), concentrated under dimin-
ished pressure and puriﬁed by column chromatography (hexane/
EtOAc, 1:1) to give 11d (235 mg, 40%) as a syrup. ½a20D ¼ 261 (c
0.19, CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.05–7.80 (m, 10H,
H-ar), 7.36–7.27 (m, 12H, H-ar), 6.97–6.95 (d, 2H, J = 9.3 Hz, H-
ar), 6.12 (dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-20), 6.04 (dd, 1H,
J = 9.3 Hz, J = 10.6 Hz, H-30), 5.89 (t, 1H, J = 9.3 Hz, H-40), 5.28 (d,
1H, J = 9.3 Hz, H-10), 4.71 (pdd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a),
4.55 (dd, 1H, J = 5.3 Hz, J = 11.9 Hz, H-60b), 4.40 (ddd, 1H,
J = 2.6 Hz, J = 5.3 Hz, J = 9.3 Hz, H-50), 3.80 (s, 3H, OMe). 13C NMR
(90 MHz, CDCl3): d = 166.0, 165.8, 165.6, 165.1 (C@O), 162.5,
160.4 (C-2oxa, C-5oxa), 133.5–114.3 (CH-ar, CIV-ar), 77.0 (C-10),
73.6, 71.8, 70.2, 69.0 (C-20, C-30, C-40, C-50), 62.9 (C-60), 55.3
(OMe). Anal. Calcd for C43H34N2O11 (754.76): C, 68.43; H, 4.54; N,
3.71. Found: C, 68.34; H, 4.61; N, 3.63.
4.4.4. 2-(4-Nitrophenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-oxadiazole (11e)
To a solution of tetrazole 10 (850 mg, 1.31 mmol) in abs. toluene
(9 mL) was added 4-nitro-benzoyl chloride (1.57 mmol). The reac-
tion mixture was reﬂuxed for 4.5 h then evaporated under dimin-
ished pressure. Crystallisation from EtOH gave 11e (635 mg, 63%)
as yellowish crystals. Mp = 158–161 C. ½a20D ¼> 297 (c 0.17,
CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.36–7.29 (m, 24H, H-ar),
6.13 (t, 1H, J = 9.3 Hz, H-20), 5.95 (dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-
30), 5.89 (dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-40), 5.29 (d, 1H,
J = 9.3 Hz, H-10), 4.70 (dd, 1H, J < 1 Hz, J = 11.9 Hz, H-60a), 4.53 (dd,
1H, J = 3.9 Hz, J = 11.9 Hz, H-60b), 4.41 (ddd, 1H, J < 1 Hz, J = 3.9 Hz,
J = 9.3 Hz, H-50). 13C NMR (90 MHz, CDCl3): d = 166.0, 165.6, 165.1,
165.0 (C@O), 164.1, 162.0 (C-2oxa, C-5oxa), 149.7 (CH-ar, CIV-ar)
133.7–128.2 (CH-ar, CIV-ar), 77.2 (C-10), 73.3, 71.8, 70.4, 68.9
(C-20, C-30, C-40, C-50), 62.8 (C-60). Anal. Calcd for C42H31N3O12
(769.73): C, 65.54; H, 4.06; N, 5.46. Found: C, 65.48; H, 4.12;
N, 5.52.
4.4.5. 2-(1-Naphthyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyr-
anosyl)-1,3,4-oxadiazole (11h)
Prepared according to method A. Yield: 75% (white solid).
Mp = 172–174 C. ½a20D ¼ 162 (c 0.21, CHCl3). 1H NMR (360 MHz,
CDCl3): d = 8.22–7.28 (m, 27H, H-ar), 6.14, 6.10, 5.90 (3  pt, 3H,
J  9.3 Hz, H-20, H-30, H-40), 5.34 (d, 1H, J = 9.3 Hz, H-10), 4.71 (dd,009), doi:10.1016/j.bmc.2009.04.036
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1H, J = 2.6 Hz, J = 11.9 Hz, H-60a), 4.55 (dd, 1H, J = 5.3 Hz, J = 11.9 Hz,
H-60b), 4.42 (ddd, 1H, J = 2.6 Hz, J = 5.3 Hz, J = 9.3 Hz, H-50). 13C NMR
(90 MHz, CDCl3): d = 166.1, 165.9 165.6, 165.2, 164.9 (C@O, C-5oxa),
160.7 (C-2oxa), 133.2–120.0 (CH-ar, CIV-ar), 77.1 (C-10), 73.6, 71.9,
70.4, 69.1 (C-20, C-30, C-40, C-50), 63.0 (C-60). Anal. Calcd for
C46H34N2O10 (774.79): C, 71.31; H, 4.42; N, 3.62. Found: C, 71.52;
H, 4.20; N, 3.64.
4.4.6. 2-(2-Naphthyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyr-
anosyl)-1,3,4-oxadiazole (11i)
Prepared according to method A. Yield: 62% (white solid).
Mp = 164–166 C. ½a20D ¼ 318 (c 0.21, CHCl3). 1H NMR
(360 MHz, CDCl3): d = 8.56–7.30 (m, 27H, H-ar), 6.12, 6.06, 5.90
(3  pt, 3H, J  9.3 Hz, H-20, H-30, H-40), 5.30 (d, 1H, J = 9.3 Hz, H-
10), 4.72 (dd, 1H, J = 2.6 Hz, J = 11.9 Hz, H-60a), 4.56 (dd, 1H,
J = 5.3 Hz, J = 11.9 Hz, H-60b), 4.40 (ddd, 1H, J = 2.6 Hz, J = 5.3 Hz,
J = 9.3 Hz, H-50). 13C NMR (90 MHz, CDCl3): d = 166.5, 166.1 165.7,
165.2, 164.9 (C@O, C-5oxa), 163.2 (C-2oxa), 133.4–120.6 (CH-ar,
CIV-ar), 77.1 (C-10), 73.6, 71.0, 70.3, 69.1 (C-20, C-30, C-40,C-50),
63.1 (C-60). Anal. Calcd for C46H34N2O10 (774.79): C, 71.31; H,
4.42; N, 3.62. Found: C, 71.55; H, 4.08; N, 3.54.
4.4.7. 2-(4-Acetoxyphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-oxadiazole (11l)
To a solution of 4-acetoxybenzoic acid (139 mg, 0.77 mmol) and
DCC (159 mg, 0.77 mmol) in abs. toluene (5 mL) was added tetra-
zole 10 (500 mg, 0.77 mmol). The reaction was heated to reﬂux
for 7 h. After cooling to rt the mixture was ﬁltered, evaporated
and puriﬁed by column chromatography (hexane/EtOAc, 2:1) to
give 11l (247 mg, 41%) as a white amorphous product.
½a20D ¼ 174 (c 0.17, CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.09–
7.81 (m, 10H, H-ar), 7.56–7.23 (m, 14H, H-ar) 6.10 (t, 1H,
J = 9.3 Hz, H-20), 5.99 (dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-30), 5.87
(dd, 1H, J = 9.3 Hz, J = 10.6 Hz, H-40), 5.26 (d, 1H, J = 9.3 Hz, H-10),
4.71 (dd, 1H, J = 2.6 Hz, J =11.9 Hz, H-60a), 4.53 (dd, 1H,
J = 11.9 Hz, J = 5.3 Hz, H-60b), 4.38 (ddd, 1H, J = 2.6 Hz, J = 5.3 Hz,
J = 9.3 Hz, H-50), 2.33 (s, 3H, OAc). 13C NMR (90 MHz, CDCl3):
d = 168.8 (COCH3), 166.1, 165.7, 165.2, 165.1 (C@O), 164.8, 161.0
(C-2oxa, C-5oxa), 153.4, 133.6–120.8 (CH-ar, CIV-ar), 77.0 (C-10),
73.5, 71.8, 70.2, 69.0 (C-20, C-30, C-40, C-50), 62.9 (C-60), 21.1
(COCH3). Anal. Calcd for C44H34N2O12 (782.77): C, 67.52; H, 4.38;
N, 3.58. Found: C, 67.58; H, 4.30; N, 3.64.
4.4.8. 2-Phenyl-5-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-
1,3,4-oxadiazole (15a)
Prepared according to method C. Yield: 78% (colourless syrup).
½a20D ¼ 30 (c 1.06, CHCl3). 1H NMR (360 MHz, CDCl3): d 8.11–
8.09 (m, 2H, H-ar), 7.61–7.45 (m, 3H, H-ar), 5.64 (t, 1H, J = 9.9 Hz,
H-20), 5.44 (d, 1H, J = 3.0 Hz, H-40), 5.23 (dd, 1H, J = 3.0 Hz,
J = 9.9 Hz, H-30), 4.86 (d, 1H, J = 10.0 Hz, H-10), 4.28–4.11 (m, 3H,
H-50, H-60a, H-60b), 2.24, 2.06, 2.02, 1.95 (4s, 12H, CH3). 13C NMR
(90 MHz, CDCl3): d = 170.5, 170.3, 170.0, 169.4 (C@O), 166.0
161.3 (C-2oxa, C-5oxa), 132.2, 129.1,127.4 (CH-ar), 123.5 (CIV-ar),
75.5, 72.1, 71.4, 67.4, 66.9 (C-10, C-20, C-30, C-40, C-50), 61.6 (C-6),
20.7, 20.6, 20.5 (CH3). Anal. Calcd for C22H24N2O10 (476.43): C,
55.46; H, 5.08; N, 5.88. Found: C, 55.28; H, 5.21; N, 5.67.
4.4.9. 2-Phenyl-5-(2,3,4-tri-O-acetyl-b-D-xylopyranosyl)-1,3,4-
oxadiazole (15b)
Prepared according to method C. Yield: 67% (colourless syrup).
½a20D ¼ 87 (c 1.05, CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.09–
8.06 (m, 2H, H-ar), 7.56–7.49 (m, 3H, H-ar), 5.43 (pt, 1H,
J = 9.2 Hz, H-2 or H-3), 5.39 (t, 1H, J = 9.2 Hz, H-2 or H-3), 5.22–
5.13 (m, 1H, H-40), 4.81 (d, 1H, J = 9.5 Hz, H-10), 4.31 (dd, 1H,
J = 5.6 Hz, J = 11.5 Hz, H-50eq), 3.53 (dd, 1H, J = 10.7 Hz, J = 11.5 Hz,
H-50ax), 2.08, 2.06, 1.95 (3s, 9H, CH3). 13C NMR (90 MHz, CDCl3):Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
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d = 170.0, 169.7 169.2, (C@O), 165.7, 161.2 (C-2oxa, C-5oxa),
132.1, 129.0, 127.1 (CH-ar), 123.2 (CIV-ar), 72.5, 71.9, 69.5, 68.5
(C-10, C-20, C-30, C-40), 67.1 (C-50), 20.3, 20.6 (CH3). Anal. Calcd for
C19H20N2O8 (404.37): C, 56.43; H, 4.99; N, 6.93. Found: C, 56.25;
H, 5.10; N, 6.80.
4.4.10. 2-Phenyl-5-(2,3,4-tri-O-acetyl-a-D-arabinopyranosyl)-
1,3,4-oxadiazole (15c)
Prepared according to method C. Yield: 57% (colourless syrup).
½a20D ¼ þ48 (c 1.188, CHCl3). 1H NMR (360 MHz, CDCl3): d = 8.11–
8.01 (m, 2H, H-ar), 7.56–7.49 (m, 3H, H-ar), 5.66 (pt, 1H,
J = 10.0 Hz, H-20), 5.46–5.44 (m, 1H, H-40), 5.24 (dd, 1H, J = 3.3 Hz,
J = 10.0 Hz, H-30), 4.80 (d, 1H, J = 9.5 Hz, H-10), 4.21 (dd, 1H,
J = 2.3 Hz, J = 13.2 Hz, H-50ax), 3.90 (dd, 1H, J = 1.2 Hz, J = 13.2 Hz,
H-50eq), 2.24, 2.04, 1.97 (3s, 9H, CH3). 13C NMR (90 MHz, CDCl3):
d = 170.3 169.9, 169.3, (C@O), 165.7, 161.4 (C-2oxa, C-5oxa),
132.0, 129.0, 127.1 (CH-ar), 123.3 (CIV-ar), 72.2, 70.8, 68.0, 67.0
(C-10, C-20, C-30, C-40), 68.5 (C-50), 20.9, 20.6, 20.4 (CH3). Anal. Calcd
for C19H20N2O8 (404.37): C, 56.43; H, 4.99; N, 6.93. Found: C, 56.38;
H, 4.91; N, 6.70.
4.5. Synthesis of hydroximoyl chlorides
4.5.1. N-Hydroxy-benzenecarboximidoyl chloride (16b)46
Prepared according to method D from benzaldehyde (1.76 g,
16.6 mmol) to afford 16b (2.51 g, 98%) as a pale yellow amorphous
solid. Rf = 0.69 (PE/EtOAc, 3/1).
4.5.2. N-Hydroxy-4-methyl-benzenecarboximidoyl chloride (16c)46
Prepared according to method D from 4-methyl-benzaldehyde
(3.6 g, 30 mmol) to afford 16c (3.85 g, 76%) as a yellow oil.
Rf = 0.37 (CH2Cl2). 1H NMR (300 MHz, CDCl3): d = 9.15 (s, 1H, OH),
7.70 (d, 2H, J = 9.0 Hz, H-ar), 7.18 (d, 2H, J = 9.0 Hz, H-ar), 2.36 (s,
3H, PhMe). 13C NMR (75 MHz, CDCl3): d = 144.1, 140.3, 131.8,
129.1, 127.0, 21.2.
4.5.3. N-Hydroxy-4-methoxy-benzenecarboximidoyl chloride
(16d)47
Prepared according to method D from 4-methoxy-benzalde-
hyde (2 g, 14.7 mmol) to afford 16d (2.12 g, 78%) as a pale yellow
amorphous solid.
4.5.4. N-Hydroxy-4-nitro-benzenecarboximidoyl chloride (16e)
Prepared according to method D from 4-nitro-benzaldehyde
(2 g, 14.1 mmol) to afford 16e (1.61 g, 91%) as a yellow solid.
Rf = 0.75 (CH2Cl2). Mp = 101–103 C. 1H NMR (300 MHz, CDCl3):
d = 8.05 (d, 2H, J = 9.0 Hz, H-3, H-5), 8.27 (d, 2H, J = 9.0 Hz, H-2,
H-6), 8.63 (s, 1H, OH). 13C NMR (75 MHz, CDCl3): d = 123.6 (C-3,
C-5), 127.9 (C-2, C-6), 137.9 (C-1), 138.1 (ClCNOH), 148.8 (C-4).
4.5.5. N-Hydroxy-4-hydroxy-benzenecarboximidoyl chloride
(16g)
Prepared according to method D from 4-hydroxy-benzaldehyde
(1.71 g, 14.0 mmol) to afford 16g (933 mg, 39%) as a pale orange
oil. Rf = 0.73 (PE/EtOAc, 3/2). 1H NMR (300 MHz, CD3SOCD3):
d = 6.83 (d, 2H, J = 8.8 Hz, H-2, H-6), 7.61 (d, 2H, J = 8.8 Hz, H-3,
H-5), 7.95 (s, 1H, PhOH), 12.01 (s, 1H, NOH). 13C NMR (75 MHz,
CD3SOCD3): d = 116.3 (C-3, C-5), 123.5 (C-1), 133.7 (C-2, C-6),
147.3 (ClCNOH), 158.0 (C-4). MS (CI, isobutene) m/z = 172.0
[M+H]+. HRMS (CI, isobutene) m/z = C7H6ClNO [M+Na]+ calcd
172.0165, found 172.0169.
4.5.6. N-Hydroxy-1-naphthalenecarboximidoyl chloride (16h)46
Prepared according to method D from 1-naphthaldehyde (2 g,
12.8 mmol) to afford 16h (1.56 g, 91%) as a brown oil. Rf = 0.84
(CH2Cl2). 1H NMR (300 MHz, CD3SOCD3): d = 7.48–7.55 (m, 3H, H-009), doi:10.1016/j.bmc.2009.04.036
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3, H-6, H-7), 7.66 (dd, 1H, J = 5.1 Hz, J = 7.2 Hz, H-8), 7.91–7.99 (m,
1H, H-4, H-5), 8,07 (m, 1H, H-2). 13C NMR (75 MHz, CD3SOCD3):
d = 124.0, 124.7, 126.0, 126.8, 127.6, 128.0, 129.4, 130.1, 130,4,
132.7, 132.8. MS (CI, isobutene)m/z = 206.0 [M+H]+. HRMS (CI, iso-
butene)m/z = C11H8ClNO [M+Na]+ calcd 206.0373, found 206.0370.
4.5.7. N-Hydroxy-2-naphthalenecarboximidoyl chloride
(16i)46,48
Prepared according to method D from 2-naphthaldehyde (3.4 g,
21.6 mmol) to afford 42 (2.84 g, 64%) as a pale orange amorphous
solid. Rf = 0.66 (CH2Cl2). 1H NMR (300 MHz, CDCl3): d = 8.81 (s, 1H,
OH), 8.30 (s, 1H, H-ar), 7.2–7.93 (m, 4H, H-ar), 7.43–7.58 (m, 2H, H-
ar). 13C NMR (75 MHz, CDCl3): d = 140.5, 134.2, 132.6, 129.5, 128.8,
128.2, 128.1, 127.6, 127.5, 126.8, 123.2.
4.5.8. 4-Benzyloxy-N-hydroxy-benzenecarboximidoyl chloride
(16j)
Prepared according to method D from 4-benzyloxy-benzalde-
hyde (3 g, 14.1 mmol) to afford 16j (1.87 g, 51%) as a pale orange
solid. Rf = 0.88 (PE/EtOAc, 9/1). Mp = 83–84 C. 1H NMR
(300 MHz, CD3SOCD3): d = 5.07 (s, 2H, OCH2Ph), 7.01 (d, 2H,
J = 9.0 Hz, H-3, H-5), 7.31–7.36 (m, 5H, OCH2Ph), 7.63 (d, 2H,
J = 9.0 Hz, H-2, H-6), 12.09 (s, 1H, OH). 13C NMR (75 MHz,
CD3SOCD3): d = 68.7 (OCH2Ph), 114.3 (C-3, C-5), 124.5 (C-1),
126.1, 126.9, 127.0, 127.3, 127.9, 127.5 (C-2, C-6), 135.9, 159.3
(ClCNOH), 178.7 (C-4). MS (CI, isobutene) m/z = 262.0 [M+H]+.
HRMS (CI, isobutene) m/z = C14H12ClNO2 [M+Na]+ calcd 262.0635,
found 262.0637.
4.5.9. N-Hydroxy-benzo[1,3]dioxole-5-carboximidoyl chloride
(16k)
Prepared according to method D from benzo[1,3]dioxole-5-
carbaldehyde (4.5 g, 30 mmol) to afford 16k (4.87 g, 81%) as a pale
brown amorphous solid. Rf = 0.76 (PE/CH2Cl2, 3/7). 1H NMR
(300 MHz, CD3SOCD3): d = 12.2 (s, 1H, OH), 7.32 (dd, 1H,
J = 8.2 Hz, J = 1.8 Hz, H-4), 7.27 (d, 1H, J = 1.8 Hz, H-6), 7.00 (d,
1H, J = 8.2 Hz, H-3), 6.10 (s, 2H, OCH2O). 13C NMR (75 MHz,
CD3SOCD3): d = 149.1, 147.6, 135.0, 126.5, 121.5 (C-4), 108.2 (C-
3), 106.1 (C-6), 101.8 (OCH2O).
4.6. [3+2] Cycloaddition reactions
4.6.1. 3-Phenyl-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-
1,2,4-oxadiazole (17b)
A solution composed of 9 (350 mg, 0.58 mmol), 16b (450 mg,
2.89 mmol) and Et3N (600 lL, 4.33 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE/EtOAc, 4:1) to afford 17b (400 mg, 94%) as a
yellow solid. Rf = 0.34 (PE/EtOAc, 4:1). Mp = 71–72 C (CH2Cl2/PE).
½a20D ¼ þ5 (c (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): d = 8.05–
7.84 (m, 10H, H-ar), 7.53–7.24 (m, 15H, H-ar), 6.12 (m, 2H, H-20,
H-30), 5.92 (t, 1H, J = 9.5 Hz, H-40), 5.30 (d, 1H, J = 9.5 Hz, H-10),
4.73 (dd, 1H, J = 2.2 Hz, J = 12.4 Hz, H-60a), 4.59 (dd, 1H, J = 4.9 Hz,
J = 12.4 Hz, H-60b), 4.43 (m, 1H, H-50). 13C NMR (75 MHz, CDCl3):
d = 173.3 (C-5oxa), 168.3 (C-3oxa), 166.0, 165.7, 165.0, 164.7
(C@O), 133.4, 133.3, 133.2, 133.0, 131.2, 129.7 (2C), 129.6 (3C),
129.3 (CIV-ar), 128.6 (2C), 128.5 (2CIV-ar), 128.4 (CIV-ar), 128.3
(2C), 128.2 (3C), 127.4 (2C), 125.9 (C-10 0), 77.2 (C-50), 73.6 (C-30),
72.4 (C-10), 70.6 (C-20), 69.0 (C-40), 62.9 (C-60). MS (LSIMS, NBA)
m/z = 725 [M+H]+. HRMS (LSIMS, NBA) m/z = C42H33N2O10 [M+H]+
calcd 725.2135, found 725.2132.
4.6.2. 3-(4-Methylphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17c)
A solution composed of 9 (385 mg, 0.64 mmol), 16c (540 mg,
3.18 mmol) and Et3N (665 lL, 4.77 mmol) was treated accordingPlease cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
D
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to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE/EtOAc, 7:3) to afford 17c (250 mg, 53%) as a
pale yellow foam. Rf = 0.40 (PE/EtOAc, 7:3). ½a20D ¼ 3 (c 1, CH2Cl2).
1H NMR (300 MHz, CDCl3): d = 8.04 (m, 2H, H-ar), 7.94 (m, 2H, H-
ar), 7.88–7.81 (m, 6H, H-ar), 7.55–7.24 (m, 12H, H-ar), 7.18 (d,
2H, J = 8.0 Hz, H-ar), 6.08 (m, 2H, H-20, H-30), 5.88 (t, 1H,
J = 9.7 Hz, H-40), 5.26 (d, 1H, J = 9.7 Hz, H-10), 4.70 (dd, 1H,
J = 2.9 Hz, J = 12.5 Hz, H-60a), 4.56 (dd, 1H, J = 5.0 Hz, J = 12.5 Hz,
H-60b), 4.40 (ddd, 1H, J = 9.7 Hz, J = 5.0 Hz, J = 2.9 Hz, H-50), 2.34
(s, 3H, CH3Ph). 13C NMR (75 MHz, CDCl3): d = 173.1 (C-5oxa),
168.4 (C-3oxa), 166.0, 165.7, 165.0, 164.7 (C@O), 141.7 (C-10 0),
133.5, 133.4, 133.3, 133.1, 129.8, 129.7 (2C), 129.4, 129.3 (CIV-ar),
128.5 (CIV-ar), 128.4, 128.3 (2C), 127.3, 123.2 (C-40 0), 77.1 (C-50),
73.7 (C-30), 72.4 (C-10), 70.6 (C-20), 69.0 (C-40), 62.9 (C-60), 21.5
(CH3Ph). MS (ESI) m/z = 739.0 [M+H]+, 740.0 [M+Na]+, 1476.6
[2M+H]+, 1498.8 [2M+Na]+. HRMS (ESI) m/z = C43H35N2O10
[M+H]+ calcd 739.2292, found 739.2293.
4.6.3. 3-(4-Methoxyphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17d)
A solution composed of 9 (300 mg, 0.5 mmol), 16d (460 mg,
2.48 mmol) and Et3N (520 lL, 3.71 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE/EtOAc, 4:1) to afford 17d (336 mg, 90%) as a
white solid. Rf = 0.17 (PE/EtOAc, 4:1). Mp = 75–76 C (CH2Cl2/PE).
½a20D ¼ 9 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): d = 8.05–7.85
(m, 10H, H-ar), 7.55–7.28 (m, 12H, H-ar), 6.89 (d, 2H, J = 8.7 Hz,
H-ar), 6.06 (m, 2H, H-20, H-30), 5.86 (m, 1H, H-40), 5.24 (m, 1H, H-
10), 4.70 (dd, 1H, J = 1.9 Hz, J = 12.3 Hz, H-60a), 4.56 (dd, 1H,
J = 4.8 Hz, J = 12.3 Hz, H-60b), 4.38 (m, 1H, H-50), 3.81 (s, 3H,
OCH3). 13C NMR (75 MHz, CDCl3): d = 173.5 (C-5oxa), 168.6 (C-
3oxa), 166.6, 166.2, 165.6 (C=O), 165.2 (C-40 0), 162.5, 134.0, 133.9,
133.8, 133.6, 130.3, 130.2, 129.9 (CIV-ar), 129.6, 129.1 (CIV-ar),
129.0 (CIV-ar), 128.9, 128.8, 128.8, 119.0 (C-10 0), 114.6 (C-30 0), 77.6
(C-50), 74.2 (C-20 or C-30), 72.9 (C-10), 71.1 (C-20 or C-30), 69.5 (C-
40), 63.4 (C-60), 55.8 (OCH3). MS (LSIMS, NBA) m/z = 755 [M+H]+.
HRMS (LSIMS, NBA) m/z = C43H35N2O11 [M+H]+ calcd 755.2241,
found 755.2242.
4.6.4. 3-(4-Nitrophenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17e)
A solution composed of 9 (378 mg, 0.62 mmol), 16e (630 mg,
3.12 mmol) and Et3N (610 lL, 4.86 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE/EtOAc, 4:1) to afford 17e (480 mg, 99%) as
an orange solid. Rf = 0.31 (PE/EtOAc, 4:1). Mp = 78–79 C (CH2Cl2/
PE). ½a20D ¼ 9 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): d = 8.21–
7.86 (m, 14H, H-ar), 7.53–7.25 (m, 10H, H-ar), 6.21 (t, 1H,
J = 9.4 Hz, H-30), 6.09 (t, 1H, J = 9.4 Hz, H-20), 5.96 (t, 1H,
J = 9.4 Hz, H-40), 5.37 (d, 1H, J = 9.4 Hz, H-10), 4.77 (dd, 1H,
J < 1 Hz, J = 12.3 Hz, H-60a), 4.62 (dd, 1H, J = 4.4 Hz, J = 12.3 Hz, H-
60b), 4.51 (m, 1H, H-50). 13C NMR (75 MHz, CDCl3): d = 174.8 (C-
5oxa), 167.3 (C-3oxa), 166.5, 166.2, 165.6, 165.4 (C@O), 149.9 (C-
100), 134.1, 133.9, 133.7, 132.3 (C-400), 130.3, 130.2 (3C), 129.8
(CIV-ar), 129.0 (CIV-ar), 128.9 (3C), 128.8 (2C), 124.4, 77.7 (C-50),
74.0 (C-30), 72.9 (C-10), 71.2 (C-20), 69.5 (C-40), 63.4 (C-60). MS
(LSIMS, NBA) m/z = 770 [M+H]+. HRMS (LSIMS, NBA) m/
z = C42H32N3O12 [M+H]+ calcd 770.1986, found 770.1983.
4.6.5. 3-(4-Hydroxyphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17g)
A solution composed of 9 (500 mg, 0.82 mmol), 16g (700 mg,
4.13 mmol) and Et3N (861 lL, 5.29 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE then PE/EtOAc, 7:3) to afford 17 g (250 mg,
41%) as a white gum. Rf = 0.73 (PE/EtOAc, 1:1). ½a20D ¼ 11:7 (c009), doi:10.1016/j.bmc.2009.04.036
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1.05, CH2Cl2). 1H NMR (500 MHz, CDCl3): d = 8.07–7.82 (m, 10H, H-
ar), 7.57–7.28 (m, 12H, H-ar), 6.85 (d, 2H, J = 8.7 Hz, H-300, H-500),
6.09–6.00 (m, 2H, H-20, H-30), 5.86 (t, 1H, J = 9.9 Hz, H-40), 5.24 (d,
1H, J = 8.8 Hz, H-10), 4.72 (pdd, 1H, J < 1 Hz, J = 12.2 Hz, H-60a),
4.57 (dd, J = 5.1 Hz, J = 12.2 Hz, H-60b), 4.43–4.36 (m, 1H, H-50).
13C NMR (125 MHz, CDCl3): d = 174.8 (C-5oxa), 173.0 (C-3oxa),
168.1, 166.2, 165.8, 165.1 (C@O), 164.8, 158.3 (C-400), 133.6 (CIV-
ar), 133.8, 133.5, 133.2, 129.9, 129.8 (C-200, C-600), 129.4, 128.6,
128.56, 128.46, 128.38, 118.7 (C-100), 115.7 (C-300, C-500), 77.2 (C-
50), 73.7 (C-30), 72.5 (C-10), 70.6 (C-20), 69.0 (C-40), 63.0 (C-60). MS
(ESI) m/z = 741.0 [M+H]+, 763.0 [M+Na]+. HRMS (ESI) m/
z = C42H32N2O11 [M+H]+ calcd 741.2084, found 741.2082.
4.6.6. 3-(1-Naphthyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17h)
A solution composed of 9 (600 mg, 0.99 mmol), 16h (1.02 g,
4.96 mmol) and Et3N (1.03 mL, 7.43 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE then PE/EtOAc, 7:3) to afford 17h (424 mg,
55%) as a dark red foam. Rf = 0.65 (PE/EtOAc, 7:3). ½a20D ¼ þ3:0 (c
1, CH2Cl2). 1H NMR (300 MHz, CDCl3): d = 8.73 (dd, J = 1.4 Hz,
J = 15.8 Hz, H-80 0), 8.06–7.85 (m, 10H, H-ar), 7.54–7.25 (m, 16H,
H-ar), 6.10 (m, 2H, H-20, H-30), 5.88 (t, 1H, J = 9.9 Hz, H-40), 5.30
(d, 1H, J = 9.0 Hz, H-10), 4.73 (dd, 1H, J = 2.9 Hz, J = 12.5 Hz, H-60a),
4.58 (dd, 1H, J = 5.2 Hz, J = 12.5 Hz, H-60b), 4.42 (ddd, 1H,
J = 2.9 Hz, J = 5.2 Hz, J = 9.9 Hz, H-50). 13C NMR (75 MHz, CDCl3):
d = 172.4 (C-5oxa), 168.8 (C-3oxa), 166.1, 165.7, 165.1, 164.8
(C@O), 133.7 (CIV-ar), 133.6, 133.5, 133.3, 131.1, 130.4 (CIV-ar),
129.8, 129.7, 129.5, 129.4 (CIV-ar), 128.6, 128.53 (CIV-ar), 128.5,
128.4, 128.3, 127.5, 126.2, 126.0, 124.9, 123.0 (CIV-ar), 77.2 (C-50),
73.6 (C-30), 72.5 (C-10), 70.7 (C-20), 69.0 (C-40), 62.9 (C-60). MS
(ESI) m/z = 775.1 [M+H]+, 797.1 [M+Na]+. HRMS (ESI) m/
z = C46H34N2O10 [M+Na]+ calcd 797.2111, found 770.2114.
4.6.7. 3-(2-Naphthyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyr-
anosyl)-1,2,4-oxadiazole (17i)
A solution composed of 9 (345 mg, 0.57 mmol), 16i (586 mg,
2.85 mmol) and Et3N (595 lL, 4.86 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE/EtOAc, 4:1) to afford 17i (342 mg, 77%) as a
pale yellow foam. Rf = 0.24 (PE/EtOAc, 4:1). ½a20D ¼ 10 (c 1,
CH2Cl2). 1H NMR (300 MHz, CDCl3): d = 8.42 (s, 1H, H-ar), 8.00–
7.90 (m, 12H, H-ar), 7.25–7.15 (m, 14H, H-ar), 6.10–6.00 (m, 2H,
H-20, H-30), 5.88 (t, 1H, J = 9.8 Hz, H-40), 5.28 (d, 1H, J = 9.4 Hz, H-
10), 4.73 (dd, 1H, J = 2.8 Hz, J = 12.5 Hz, H-60a), 4.58 (dd, 1H,
J = 5.0 Hz, J = 12.5 Hz, H-60b), 4.41 (ddd, 1H, J = 2.8 Hz, J = 5.0 Hz,
J = 9.8 Hz, H-50). 13C NMR (75 MHz, CDCl3): d = 173.4 (C-5oxa),
168.5 (C-3oxa), 166.1, 165.8, 165.1, 164.8 (C@O), 134.6 (CIV-ar),
133.6, 133.5, 133.4, 133.2, 132.8 (CIV-ar), 129.8, 129.7, 129.4,
128.8, 128.6, 128.5 (CIV-ar), 128.4, 128.3, 128.2, 127.8, 127.5,
126.7, 123.7, 123.4 (CIV-ar), 77.2 (C-50), 73.6 (C-30), 72.6 (C-10),
70.6 (C-20), 69.0 (C-40), 63.0 (C-60). MS (ESI) m/z = 775.0 [M+H]+,
1549.7 [2M+H]+, 1570.8 [2M+Na]+. HRMS (ESI) m/z = C46H35N2O10
[M+H]+ calcd 775.2292, found 775.2293.
4.6.8. 3-(4-Benzyloxyphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17j)
A solution composed of 9 (222 mg, 0.37 mmol), 16j (482 mg,
1.83 mmol) and Et3N (383 lL, 2.75 mmol) was treated according
to method E. The residue was puriﬁed by ﬂash silica gel column
chromatography (PE then PE/EtOAc, 7:3) to afford 17j (211 mg,
69%) as a deep red foam. Rf = 0.40 (PE/EtOAc, 7:3). ½a20D ¼ 14:0
(c 1, CH2Cl2). 1H NMR (500 MHz, CDCl3): d = 8.09–8.03 (m, 2H, H-
ar), 7.95 (d, 2H, J = 7.0 Hz, H-200, H-600), 7.92–7.87 (m, 6H, H-ar),
7.58–7.31 (m, 17H, H-ar), 7.00 (d, 2H, J = 8.5 Hz, H-300, H-500), 6.07
(m, 2H, H-30, H-40), 5.87 (t, 1H, J = 9.5 Hz, H-20), 5.23 (d, 1H,Please cite this article in press as: Tóth, M.; et al. Bioorg. Med. Chem. (2E
D
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J = 9.5 Hz, H-10), 5.12 (s, 2H, OCH2Ph), 4.72 (dd, 1H, J = 3.0 Hz,
J = 17.5 Hz, H-60a), 4.58 (dd, 1H, J = 5.0 Hz, J = 17.5 Hz, H-60b),
4.40 (ddd, 1H, J = 3.0 Hz, J = 5.0 Hz, J = 10.0 Hz, H-50). 13C NMR
(125 MHz, CDCl3): d = 173.0 (C-5oxa), 168.1 (C-3oxa), 166.1,
165.8, 165.1, 164.7 (C@O), 161.2 (C-400), 136.3 (CIV-ar), 133.6,
133.4, 133.3, 133.2, 129.9, 129.8 (CIV-ar), 129.4, 129.2, 128.6 (CIV-
ar), 128.4, 128.3 (OCH2Ph), 128.1, 127.5, 118.8 (C-10), 115.0 (C-300,
C-500), 77.2 (C-50), 73.7 (C-20), 72.5 (C-10), 70.6 (C-30), 70.0 (OCH2Ph),
69.0 (C-40), 63.0 (C-60). MS (ESI) m/z = 831.1 [M+H]+, 853.2
[M+Na]+. HRMS (ESI) m/z = C49H38N2O11 [M+Na]+ calcd 853.2373,
found 853.2375.
4.6.9. 3-(1,3-Benzodioxol-5-yl)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,2,4-oxadiazole (17k)
A solution composed of 9 (300 mg, 0.49 mmol), 16k (494 mg,
2.48 mmol) and Et3N (518 lL, 3.72 mmol) was treated according to
method E. The residue was puriﬁed by ﬂash silica gel column chro-
matography (PE/EtOAc, 4:1) to afford 17k (282 mg, 74%) as a white
foam. Rf = 0.18 (PE/EtOAc, 4:1). ½a20D ¼ 11:0 (c 1, CH2Cl2). 1H NMR
(300 MHz, CDCl3): d = 8.06–7.82 (m, 8H, H-ar), 7.57–7.23 (m, 14H,
H-ar), 6.79 (d, 1H, J = 8.1 Hz, H-ar), 6.08 (t, 1H, J = 9.5 Hz, H-20),
6.03 (t, 1H, J = 9.5 Hz, H-30), 5.97 (s, 2H, OCH2O), 5.86 (t, 1H,
J = 9.5 Hz, H-40), 5.22 (d, 1H, J = 9.5 Hz, H-10), 4.70 (dd, 1H,
J = 2.9 Hz, J = 12.4 Hz, H-60a), 4.55 (dd, 1H, J = 5.2 Hz, J = 12.4 Hz, H-
60b),4.38 (ddd, 1H, J = 2.9 Hz, J = 5.2 Hz, J = 9.5 Hz, H-50). 13C NMR
(75 MHz, CDCl3): d = 173.1 (C-5oxa), 168.1 (C-3oxa), 166.1, 165.7,
165.0, 164.7 (C@O), 150.2 (CIV-ar), 148.0 (CIV-ar), 133.5, 133.4,
133.3, 133.1, 129.8, 129.7, 129.4 (CIV-ar), 128.5 (CIV-ar), 128.4,
128.3, 122.5, 119.8 (CIV-ar), 108.5, 107.4, 101.5 (OCH2O), 77.1 (C-
50), 73.6 (C-20), 72.4 (C-10), 70.6 (C-30), 69.0 (C-40), 62.9 (C-60). MS
(ESI) m/z = 769 [M+H]+, 1537 [2 M+H]+, 1559 [2 M+Na]+. HRMS
(ESI)m/z = C43H33N2O12 [M+H]+ calcd 769.2033, found 769.2035.
4.7. Enzymology
Glycogen phosphorylase b was prepared from rabbit skeletal
muscle according to the method of Fischer and Krebs,42 using dithi-
othreitol instead of L-cysteine, and recrystallized at least three
times before use. Kinetic experiments were performed in the direc-
tion of glycogen synthesis as described previously.43 Kinetic data
for the inhibition of rabbit skeletal muscle glycogen phosphorylase
were collected using different concentrations of a-D-glucose-1-
phosphate (2–20 mM), constant concentrations of glycogen (1%
w/v) and AMP (1 mM), and various concentrations of inhibitors.
Inhibitors were dissolved in dimethyl sulfoxide (DMSO) and di-
luted in the assay buffer (50 mM triethanolamine, 1 mM EDTA
and 1 mM dithiothreitol) so that the DMSO concentration in the as-
say should be lower than 1%. The enzymatic activities were pre-
sented in the form of double-reciprocal plots (Lineweaver–Burk)
applying a nonlinear data analysis program. The inhibitor con-
stants (Ki) were determined by Dixon plots, by replotting the
slopes from the Lineweaver–Burk plots against the inhibitor con-
centrations.17,44 The means of standard errors for all calculated ki-
netic parameters averaged to less than 10%.
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